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1. Introduction 1 
1. Introduction 
Guanosine-5’-triphosphate (GTP) represents a major energy source for diverse biological 
processes and serves as key substrate in a large number of enzymatic reactions in both 
eukaryotes and prokaryotes. In the citric acid cycle, GTP is the only energy equivalent 
being produced after hydrolysis of succinyl-CoA to succinate by succinyl-CoA 
synthetase1. During protein biosynthesis, GTP bound to the elongation factor Tu (EF-Tu) 
is required as energy donor for the amino acid attachment to the developing 
polypeptide2. 
 The central role of GTP, however, is its function as substrate for signal 
transducing enzymes. So far, GTP is known to be involved in four major signaling 
systems: (1) Small GTP-binding proteins constitute a large superfamily of low molecular 
mass proteins involved in the regulation of a wide variety of cellular functions3. (2) 
Heterotrimeric GTP-binding proteins represent an important class of high molecular mass 
proteins which transduce signals from G-protein-coupled receptors to intracellular 
effector systems4. (3) Guanylyl cyclases (GCs) synthesize the second messenger cyclic 
3’:5’-guanosine monophosphate (cGMP) which regulates very diverse processes such as 
cellular growth and contractility, cardiovascular homeostasis, inflammation, sensory 
transduction, and neuronal plasticity and learning5. (4) The bacterial second messenger 
cyclic 3’:5’-di-guanosine monophosphate (c-di-GMP) is produced from GTP by di-
guanylate cyclases (DGCs) and controls a range of functions including developmental 
transitions, biofilm formation, and the virulence of pathogens6. 
 GTP-binding and -converting proteins have been extensively characterized during 
the last decades. Hence, the detailed and still growing knowledge about the molecular 
mechanisms reveals these proteins as major pharmacological targets for the 
development of novel drugs. Therefore, effective detection and quantitation methods for 
GTP turnover are essential and can offer a stable platform for the establishment of new 
therapies. 
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1.1 Small GTP-Binding Proteins 
Small GTP-binding proteins comprise a superfamily of more than 100 members which 
have been identified in eukaryotes7,8. According to their respective cellular functions 
these members are classified into five subfamilies: Ras, Rho/Rac/Cdc42, Rab, Arf, and 
Ran9. Small GTP-binding proteins have molecular masses ranging from 20 to 40 kDa and 
show high structural homology which is characterized by conserved amino acid 
sequences essential for specific GTP- and GDP-binding as well as GTPase activity10,11. 
Small GTP-binding proteins are either found in the cytosol or attached to membranes. 
The Ras, Rho/Rac/Cdc42, and Rab subfamilies undergo posttranslational modifications at 
the C-terminus with lipophilic groups enabling interactions with membraneous structures 
necessary for their biological function12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Regualtion of the activity of small GTP-binding proteins. GAP: GTPase activating protein, 
GEF: guanine nucleotide exchage factor. 
 
 Small GTP-binding proteins act as molecular switches by cycling between an 
inactive, GDP-bound state and an active, GTP-bound form (see Fig. 1.1)13. The 
dissociation of GDP from the inactive form is induced by upstream signals and followed 
by GTP-binding. In the active, GTP-bound state, small GTP-binding proteins interact with 
downstream effectors via their downstream effector-binding regions and evoke diverse 
cellular responses. Inactivation of the GTP-bound state is achieved by GTP hydrolysis to 
GDP and Pi due to the intrinsic GTPase activity of small GTP-binding proteins. However, 
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both, the dissociation of GDP from the inactive state and GTP hydrolysis are intrinsically 
very slow. The GDP/GTP exchange process is stimulated by guanine nucleotide exchange 
factors (GEFs) the action of which is mostly regulated by upstream signals. The intrinsic 
GTPase activity is enhanced by GTPase activating proteins (GAPs). Most of the GEFs14,15 
and GAPs14,16 are specific for each subfamily of small GTP-binding proteins. 
 
1.1.1 Ras Proteins 
The members of the Ras subfamily function mainly as regulators of gene expression. 
Fig. 1.2 indicates the mode of action of Ras proteins in gene expression. Activity of Ras 
proteins is triggered by various extracellular signals which mostly activate receptors with 
tyrosine kinase activity17. So-called adaptor proteins such as SHC and GRB2 bind to 
phosphotyrosines and than form complexes with SOS, a Ras-GEF. SOS activates 
membrane-bound Ras proteins by inducing GDP-GTP exchange. Gene expression by Ras 
proteins is subsequently initiated by a series of several kinases following the mitogen-
activated protein (MAP) kinase cascade: activated Ras proteins directly bind to the Raf 
protein18 which phosphorylates and activates MEK (MAPK/ERK kinase)19 which in turn 
phosphorylates and activates ERK (extracellular regulated kinase)20. ERK translocates 
into the nucleus and activates transcription factors21. It is estimated that in about 30% 
of all human tumors mutated Ras oncogenes are present22, emphasizing the great 
impact of abnormal Ras activity in carcinogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 Regulation of gene expression by Ras proteins (modified from Vojtek and Der23). RTK: 
receptor tyrosine kinase; SHC and GRB2: adapter proteins binding to phosphotyrosines; SOS: Son of 
sevenless (GEF); Raf: rapidly growing fibrosarcoma (protein kinase); MEK: MAPK/ERK kinase; ERK: 
extracellular regulated kinase; TF: transcription factor. 
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1.1.2 Rho/Rac/Cdc42 Proteins 
The main function of Rho/Rac/Cdc42 proteins is the regulation of cytoskeletal 
reorganization in response to extracellular signals24. There are also hints for 
Rho/Rac/Cdc42 proteins to be involved in gene expression25,26. The actin cytoskeleton 
represents a network of actin filaments and specialized proteins located in the cytoplasm 
of cells27. Actin filaments can be structurally classified into three groups: (1) actin stress 
fibres consisting of bundles of actin filaments which traverse the cell and are linked to 
the extracellular matrix, (2) lamellipoda, a thin, two-dimensional actin mesh 
characterized by regularly occurring membrane ruffles found mostly at the edge of 
mobile cells and cultured fibroblasts, and (3) filopodia representing narrow, cytoplasmic 
projections containing bundles of cross-linked actin filaments found in motile cells and at 
neuronal growth cones (see Fig. 1.3). The formation of these three discrete structures is 
regulated by Rho28, Rac29, and Cdc4230, respectively. 
 
   
Fig. 1.3 Images of fluorescently labeled cells showing (a) stress fibres of rat aortic vascular smooth 
muscle cells (taken from Deshpande et al.31), (b) lamellipodium of human fibroblasts (cell line SV80) 
(http://www.umm.de/1425.0.html, 06-02-2010), and (c) filopodia at neuronal growth cone of 
neuroblastoma cells (cell line NG108-15) (taken from Nozumi et al.32). 
 
 In addition to GEFs and GAPs controlling the activity of Rho/Rac/Cdc42 proteins 
as described above, a third class of regulatory units plays an important role for 
Rho/Rac/Cdc42 protein activity: GDP dissociation inhibitors (GDIs) stabilize the inactive 
GDP-bound form via formation of stable complexes with Rho/Rac/Cdc42 proteins which 
have been posttranslationally modified with lipophilic groups. Hence, it is possible for 
Rho/Rac/Cdc42 proteins to remain soluble in the cytosol. 
 
a c b 
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1.1.3 Rab Proteins 
The Rab protein subfamily is the largest 
within the small GTP-binding protein 
superfamily. Rab protein activity is 
focused on the regulation of 
intracellular vesicle trafficking which is 
responsible for the transport of both 
transmembrane and secreted, soluble 
proteins between different membrane 
compartments. Essential cellular 
functions such as exocytosis, 
endocytosis, and cytokinesis are 
dependent on vesicle trafficking33. 
Intracellular vesicle trafficking is 
generally divided into four steps (see Fig. 1.4): (1) budding of vesicles from a donor 
membrane, (2) targeting and (3) docking of vesicles to an acceptor membrane, and (4) 
fusion with the acceptor membrane3. The budding process, however, is mainly regulated 
by Arf proteins (see section 1.1.4). Due to the interaction with membranous structures, it 
is necessary for Rab proteins to be modified with lipids. The most common 
posttranslational modification is the geranylgeranylation of cysteine residues at the 
highly variable C-terminal region which is essential for specific recognition of target 
membranes34. 
 Rab protein activity is controlled by three regulatory units: GEF, GAP, and GDI 
(see Fig. 1.5). GDI interacts with GDP-bound Rab proteins which are maintained in the 
cytosol. After release of GDI, the GDP bound form is converted into the active GTP-
bound state by the action of a GEF. The active Rab form interacts with effectors coupled 
to transport vesicles leading to recruitment of the vesicles to the target membrane. 
Inactivation occurs via action of a GAP and the GDP-bound form is stabilized in the 
cytosol by GDIs again35. Due to this membrane association/dissociation cycle 10-50% of 
a specific Rab protein are located in the cytosol. 
 
 
 
 
 
 
 
Fig. 1.4 Principle mechanism of intracellular vesicle 
trafficking. Modified from Takai et al.3 
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Fig. 1.5 Regulation of Rab protein activity and related translocation (modified from Takai et al.3). 
GDI: GDP dissociation inhibitor; GEF: Guanine nucleotide exchange factor; GAP: GTPase activating 
protein. 
 
1.1.4 Arf Proteins 
Arf (ADP-ribosylation factor) proteins play an important role in the budding process (see 
Fig. 1.4) of vesicle trafficking36. For this process, it is necessary that specific proteins 
coat the cytoplasmic face of a donor membrane. Such coat proteins are able to 
recognize distinct membrane receptors and mechanically support the formation of vesicle 
buds (see Fig. 1.6)37. Arf proteins are involved in the recruitment of coat proteins to the 
membrane. Their activity is regulated by specific GEFs and GAPs, but not GDIs. GDP-
bound Arf proteins are present in the cytosol and undergo protein-membrane interaction 
after activation by GEFs. The membrane association is further stabilized by a 
conformational change of the N-terminal α-helix resulting in the interaction of several 
hydrophobic amino acid residues with the membrane. After vesicle budding, Arf proteins 
are deactivated by cytosolic GAPs which are recruited to the membrane3. Subsequent 
targeting, docking, and fusion steps are regulated by Rab proteins (see section 1.1.3). 
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Fig. 1.6 Regulation of Arf protein activity and budding of vesicle from donor membrane (modified 
from Takai et al.3). GEF: guanine nucleotide exchange factor; GAP: GTPase activating protein. 
 
1.1.5 Ran Proteins 
Ran proteins (Ras-related nuclear proteins) represent the smallest subfamily of small 
GTP-binding proteins and play a central role in nucleocytoplasmic transport processes 
which are necessary for the transport of large molecules including proteins and RNAs38. 
Cargo molecules carrying the nuclear localization signal (NLS) (for import) or the nuclear 
export signal (NES) (for export) are 
recognized and bound by transport 
receptors, so called importins or 
exportins, respectively, and are 
transported through the nuclear 
pore complex (NPC) – a large 
protein complex spanning the 
nuclear envelope39. In some cases, 
the cargo-receptor interaction is not 
direct but mediated by adaptor 
molecules. 
 Ran proteins undergo 
activation and inactivation by GEFs 
and GAPs, respectively, (see 
Fig. 1.7) which are unevenly 
distributed in the nucleus and the 
cytoplasm. Hence, activated Ran 
Fig. 1.7 Regulation of Ran protein activity and 
nucleocytoplasmic export process (modified from Takai 
et al.3).C: cargo molecule; E: exportin; NPCs: nuclear 
pore complexes; GAP: GTPase activating protein; GEF: 
guanine nucleotide exchange factor. 
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proteins are mostly located in the nucleus whereas inactive Ras proteins are found in the 
cytoplasm3. For export processes, GTP-bound Ran protein and the cargo molecule bind 
to the exportin and the resulting complex is transported through the NPC to the 
cytoplasm where the Ran protein is deactiveated by a GAP. As a consequence, 
dissociation of the transport complex is induced, the cargo molecule is released, and the 
free exportin is reimported to the nucleus again. Inactive Ran proteins are stabilized by 
GDIs which are necessary for the transport back into the nucleus. Nuclear import 
processes follow another mechanism where Ran proteins are not necessary for the 
transport itself but for the dissociation of the transport complex40. 
 
 
1.2 Heterotrimeric GTP-Binding Proteins 
1.2.1 Signaling Mechanism of Heterotrimeric GTP-Binding Proteins  
Heterotrimeric GTP-binding proteins (G-proteins) are central constituents of signal 
transduction and transduce extracellular information from ligand-binding to G-protein 
coupled receptors (GPCRs) into intracellular responses41. GPCRs form the initial part of 
the signal transduction cascade and consist of 7 transmembrane α-helices, an 
extracellular amino-terminal segment and an intracellular carboxy-terminal tail42. These 
receptors are the pharmacological targets of 50-60% of all existing drugs. 
Active GPCRs specifically interact with G-proteins consisting of a Gα-subunit and a 
Gβ/γ heterodimer both of which are located on the cytosolic side of the membrane. The 
G-protein activation/inactivation cycle is shown in Fig. 1.8. In the inactive state, the Gα 
subunit is GDP-bound and associated with the Gβγ unit to form a heterotrimeric complex. 
After activation of the GPCR in response to agonist binding, the resulting conformational 
change induces the release of GDP from the Gα subunit and its replacement by GTP. 
Hence, the GPCR acts as guanine nucleotide exchange factor (GEF). Subsequent 
conformational changes of the Gα subunit in the active, GTP-bound form promote the 
separation of Gα subunit and Gβγ complex each of which can interact with specific 
effector proteins (see section 1.2.2). The intrinsic GTPase activity of the Gα subunit 
terminates function via hydrolysis of the terminal phosphate of bound GTP. 
Reassociation of the GDP-bound Gα subunit with the Gβγ complex completes the G-
protein cycle43. G-proteins display a higher rate of GTP hydrolysis than small GTP-binding 
proteins, but it is still relatively low44. The GTPase activity is accelerated by regulators of 
1. Introduction 9 
G-protein signaling (RGS), which act as GTPase activating proteins (GAPs) analoguously 
to small GTP-binding proteins (see section 1.1)45. 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 Structure and Function of Heterotrimeric GTP-Binding Protein-Subunits 
Since the first steps for the identification of the three subunits of heterotrimeric GTP-
binding proteins were made in the early 1980s by Rodbell and Gilman46 who were 
awarded the Nobel Prize for Physiology or Medicine in 199447,48, structural and functional 
relationships of G-proteins have been intensively investigated. 
The Gα subunits are a family of proteins with molecular masses ranging from 39-
53 kDa and display an amino acid similarity of about 45-80%49. Gα subunits have been 
divided into four main classes according to their amino acid sequences50: (1) Gsα which 
mainly mediates hormonal stimulation of adenylyl cyclase, (2) Gi/oα involved in inhibition 
of adenylyl cyclase and opening and closing of K+- and Ca2+-channels, respectively, (3) 
Gq/11α whose members are primarily related to phospholipase C activity, and (4) G12/13α 
whose function was only lately determined and shown to be involved in G-protein-linked 
signaling pathways and cell responses51. A detailed classification of Gα subunits and 
corresponding functions are shown in Table 1.1. 
Gα proteins consist of two domains. The first domain, also referred to as Ras-like 
domain, contains a six-stranded β-sheet surrounded by five α-helices. It is responsible 
for guanine nucleotide binding and GTPase activity52. The second domain is completely 
α-helical and buries the GTP in the core of the protein53. Gα subunits are no 
transmembrane polypeptides and should therefore be soluble proteins. In fact, all Gα 
subunits are posttranslationally modified with lipids at or near the amino terminus54. 
Fig 1.8 Activation/inactivation cylce of 
heterotrimeric G-proteins after GPCR 
stimulation (taken from Milligan and 
Kostenis43). RGS: regulator of G-protein 
signaling. 
βγ effectors 
GTPase 
2nd 
messenger 
system 2nd 
messenger  
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They can be either myristoylated at an amino-terminal glycine residue or covalently 
modified with palmitate via a thioester linkage to a cysteine residue or both. Hence, Gα 
subunits can be present at the plasma membrane in order to interact with specific 
receptors. 
 
Table 1.1 Heterotrimeric GTP-binding proteins: classification, main effectors, and related diseases 
(modified from Milligan and Kostenis43). 
Family Subclass Effectors Related diseases 
Gsα Gs(S)α 
Gs(L)α 
Gs(XL)α 
Golfα 
Adenylyl cyclases (Gs,s(XL), olfα) 
Maxi K channel (Gsα) 
Src tyrosine kinases (Gsα) 
GTPase of tubulin (Gsα) 
Gs(XL)α: brachydactyly, trauma-related 
bleeding tendency, neurological 
problems 
Gsα: McCune-Albright syndrome, 
cholera, pseudohypoparathyroidism 
type Ia/b, testotoxicosis, adenomas of 
pituitary and thyroid 
 
 
Gi/oα 
 
Go1α 
Go2α 
Gi1-i3α 
Gzα 
Gt1/2α 
Ggustα 
 
Adenylyl cyclase (Gi,o,zα) 
Rap1GAPII-dependent 
ERK/MAPkinase activation (Giα) 
Ca2+ channels (Gi,o,z,α) 
K+ channels (Gi,o,z,α) 
GTPase of tubulin (Giα) 
Src tyrosine kinases (Giα) 
cGMP-PDE (Gt/gustα) 
 
 
Giα: whooping cough, adrenal and 
ovarian adenomas 
Gtα: congenital cone dysfunction, night 
blindness 
 
Gq/11α 
 
Gqα 
G11α 
G14α 
G15α 
G16α 
 
 
Phospholipase Cβ isoforms 
p63-RhoGEF (Gq/11α) 
Bruton’s tyrosine kinase (Gqα) 
K+ channels (Gqα) 
 
Gq/11α: dermal hyperpigmentation and 
melanocytosis? 
 
G12/13α 
 
Gα12 
Gα13 
 
Phospholipase D 
Phospholipase Cε 
NHE-1 
iNOS 
E-cadherin-mediated cell adhesion 
P115-RhoGEF 
PDZ-RhoGEF 
 
 
Recent SNPs identified but no disease 
correlation yet 
 
Gβ/γ 
 
β1-5 
γ1-12 
 
PLCβs 
Adenylyl cyclase I 
Adenylyl cyclases II, IV, VII 
PI-3 kinases 
K+ channels 
Ca2+ channels 
 
 
Gβ3: atherosclerosis, hypertension, 
metabolic syndrome 
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The Gβγ unit is a tightly complexed dimer which only dissociates under denaturing 
conditions55. It interacts with the inactive Gα subunit and helps to increase its affinity for 
specific receptors. Although initially the Gβγ subunit was believed to only interact with 
Gα in order to control signaling and recruitment to the membrane due to its hydrophobic 
character, it has become clear that the Gβγ subunit itself interacts with a large number 
of effectors (see Table 1.1)4. Thus far, five Gβ and twelve Gγ subunits are known for 
which a high number of possible pairings is possible. However, only a small set of those 
Gβγ dimers is essentially formed. 
The Gβ subunits are highly conserved sharing 50-83% identity with a molecular 
mass of 35-36 kDa. The amino-terminal region consists of an amphiphatic α-helix and 
the carboxy-terminus is composed of seven repeating units of 43 amino acids each55. 
The Gγ subunit is a much smaller group of proteins of 6-9 kDa. They are more diverse 
resulting from posttranslational modifications56. Gγ subunits undergo either farnesylation 
or gernanylgeranylation at the carboxy-terminus. In contrast to Gβ subunits, Gγ proteins 
only share 27-75% homology and are thus thought to account for the functional 
specificity of Gβγ complexes55. The tight interaction of the Gβ and Gγ subunit is based on 
a non-covalent mechanism and the association occurs in the cytosol prior to membrane 
attachment. 
 
 
1.3 Guanylyl Cyclases 
1.3.1 Structure and Regulation of Guanylyl Cyclases 
In the late 1960s cyclic 3’:5’-guanosine monophosphate (cGMP) was first identified as 
natural product of guanylyl cylcase (GC) activity57. It took until the mid-1970s to discover 
the existence of different forms of GCs58. Today, two types of GCs are known, soluble GC 
(sGC) and membrane-bound, particulate GC (pGC) which are partly homologous but 
strongly differ with respect to cellular localization, structure, and regulation5. Since the 
discovery of cGMP, a complex concept of cGMP signaling has been established which is 
still being expanded (see Fig. 1.9). 
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Fig. 1.9 Concept of cGMP signaling (modified from Feil and Kemp-Harper59). cGMP generators and 
effectors are shown in green and orange, respectively. NOS: nitric oxide synthase; sGC: soluble 
guanylyl cyclase; pGC: particulate guanylyl cyclase; cGKs: cGMP-dependent protein kinases; PDEs: 
phosphodiesterases. 
 
 sGC is a heterodimer which consists of two subunits, α and β and is stimulated by 
nitric oxide (NO) leading to a 200-fold increase in GC activity60. So far, four sGC subunits 
have been identified: α1, α2, β1, and β2. Only heterodimeric enzymes are active61. sGC 
exists as β1 α1 and β1 α2 isoform whereas isolated homodimers (α1 α1 and β1 β1) do not 
show any GC activity62. NO is synthesized by the nitric oxide synthase (NOS) from L-
arginine. There are three forms of NOS: endothelial, neuronal, and inducible NOS (eNOS, 
nNOS, and iNOS)63. After NO synthesis, the stimulator rapidly diffuses across cell 
membranes and activates sGC. The sensitivity of sGC to NO is based on the presence of 
a heme group in the heterodimer. The heme group is bound to the amino-terminal 
region of the β chain of sGC via an imidazole residue (His-105 of β1 subunit) coordinating 
the heme group in axial position64. Binding of NO to the central heme-iron yields the 
formation of a pentacoordinated complex and breaks the bond to the axial His-105 
thereby activating the enzyme as a result of conformational changes65. The catalytic 
domain is located at the carboxy-terminal half of sGC and consists of components from 
both α and β subunit.  
 Besides sGC there are at least seven plasma membrane GCs (GC-A through GC-G) 
which are partly homologous to sGC but have a distinct topology. pGCs consist of an 
extracellular ligand-binding domain, a short transmembrane region, and an intracellular 
 
NOS 
L-arginine + O2 L-citrulline + NO 
Natriuretic 
peptides 
sGC 
GTP 
cGMP 
pGC 
Cation 
channel
s 
cGKs PDEs 
GMP 
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domain that contains the catalytic region at its carboxy-terminus66. The intracellular 
region contains a protein kinase-homology domain (KHD), an amphiphatic α-helical or 
hinge region, and a carboxy-terminal cyclase-homology catalytic domain (see Fig. 1.10). 
 
 
 
 
 
 
 
 
 
Although the KHD has many amino acid residues conserved in the catalytic 
domain of protein kinases, no such activity has been detected yet. The KHD is known to 
modulate the GC activity of the cyclase-homology catalytic domain67 and may serve as 
docking site for direct interactions between the pGC and other proteins68. The coiled-coil 
hinge region is responsible for oligomerization of pGCs. The cyclase catalytic domain is 
only activated after dimerization although each pGC peptide chain contains one catalytic 
domain. Specific ligands for the extracellular receptor domain have only been identified 
for four of the seven known pGCs, the other three forms are assumed to be orphan 
receptors69. In contrast to sGCs, pGCs are activated by various peptides70. The specific 
ligands and the functions of the different pGCs are displayed in table 1.2. 
 
Table 1.2 Particulate guanylyl cyclases: specific ligands and main functions (modified from Schmidt 
et al.70). ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; CNP: C-type natriuretic 
peptide. 
Receptor Ligands Functions 
 
GC-A 
 
 
GC-B 
 
 
GC-C 
 
 
 
GC-D 
 
GC-E 
 
GC-F 
 
GC-G 
 
 
ANP, BNP 
 
 
CNP 
 
 
Heat-stable enterotoxins, 
guanylin, uroguanylin 
 
 
Guanylin, uroguanylin 
 
Orphan 
 
Orphan 
 
Orphan 
 
 
Decrease in arterial blood pressure and volume, inhibition 
of cardiomyocyte growth and cardiac fibrosis 
 
Inhibition of cardiomyocyte growth, vascular regeneration, 
endochondral ossification 
 
Increased intestinal electrolyte and water transport, 
epithelial cell growth and differentiation, diuresis, 
natriuresis? 
 
Pheromone detection?, salt and water homeostasis? 
 
Vision, survival of cones 
 
Vision 
 
Renal protection? 
 
Fig 1.10 Predicted homodimeric topology of 
particulate guanylyl cyclases (modified from 
Kuhn66). KHD: kinase homology domain; GC: 
guanylyl cyclase. 
 
Extracellular 
domain 
Membrane 
KHD 
Hinge region 
GC domain 
GTP cGMP 
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1.3.2 Effectors of Cyclic 3’:5’-Guanosine Monophosphate 
cGMP synthesized by GCs can regulate cellular functions via interaction with different 
effectors (see Fig. 1.9): cyclic nucleotide-gated (CNG) channels, cGMP-dependent 
protein kinases (cGKs), and phosphodiesterases (PDEs).  
 CNG channels belong to the superfamily of pore-loop channels. The topology of 
CNG channel subunits is characterized by six transmembrane domains (S1-S6), a 
reentrant pore loop between S5 and S6, and cytosolic amino- and carboxy-termini. CNG 
channels exist as tetramers with four subunits arranged around a central pore71. CNG 
channels are ion channels which are activated by the binding of cGMP or cAMP to a 
cyclic nucleotide binding domain (CNBD). They translate changes of intracellular 
concentrations of cyclic nucleotides into changes of membrane potential and Ca2+ 
concentration. CNG channels have been originally discovered in photoreceptors and 
olfactory receptor neurons where they play a central role in sensory transduction72. For 
example, in rods and cones the CNG channel is kept in an open state in presence of a 
high cGMP concentration in the dark. The resulting influx of Ca2+ and Na+ depolarizes 
the photoreceptor. After activation of rhodopsin by light, cGMP is hydrolyzed by the 
action of a PDE. The lower cGMP concentration leads to the closure of the CNG channel, 
resulting in membrane hyperpolarization73. In contrast to phototransduction, olfactory 
transduction is significantly more diverse74. 
 cGKs are serine/threonine kinases widely distributed in eukaryotes. cGKI and 
cGKII are encoded by the cGK genes prkg1 and prkg2, respectively. In mammals, the 
two isozymes cGKIα and cGKIβ are present75. cGKs are composed of two domains, a 
regulatory (R) domain and a catalytic (C) domain. The R domain consists of the amino-
terminal and the cGMP-binding domain. The latter is further divided into the high 
(cGMP I)- and low (cGMP II)-affinity binding pocket. Upon cGMP binding in both pockets, 
a pronounced change in secondary structure occurs resulting in a more elongated 
structure76. As a consequence, the inhibition of the catalytic domain containing the 
MgATP- and peptide-binding pockets is released and phosphorylation of serine and 
threonine residues in target proteins can take place. The main function of the amino-
terminal region is dimerization of cGK monomers through a leucine zipper and the 
targeting of cGKs to specific subcellular localizations77. The identification of cGK 
substrates is essential in order to understand the underlying signaling mechanisms. 
Various cGK substrates have been found, and the knowledge of cGK effects in different 
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processes such as smooth and cardiac muscle relaxation and proliferation, inhibition of 
platelet function and hippocampal learning could be expanded78. 
 Since the discovery of PDE activity in 1962, the PDE family has been expanded 
continuously. Currently, 11 gene families based on their sequence homologies and 
functional characteristics with a total of 21 genes are described79. On the one hand, 
PDEs hydrolyze cAMP or cGMP: PDE5, PDE6, and PDE9 selectively break down cGMP 
whereas PDE4, PDE7, and PDE8 hydrolyze cAMP. The remaining PDEs (PDE1, PDE2, 
PDE3, PDE10, PDE11) exhibit dual enzymatic specificity and accept both cyclic 
nucleotides as substrate. On the other hand, PDEs function as downstream effectors in 
the cGMP signaling system. Thereby, PDEs can be regulated either directly by binding of 
cGMP to regulatory domains or indirectly via phosphorylation events induced by 
interaction of cGMP with cGKs. Phosphorylation can induce both stimulation and 
inhibition of PDE activity. Moreover, cross-talk between cGMP and cAMP signaling can 
occur. The activity of PDEs catalyzing the hydrolysis of cAMP can be regulated in a 
cGMP-dependent manner or vice versa80. Thus, the levels of cyclic nucleotides can be 
fine-tuned and even small changes in cyclic nucleotide concentrations can be signaled. 
Diverse processes are related to cGMP signaling such as contraction of cardiac and 
smooth muscle, platelet aggregation, secretion, immune cell response and inflammation, 
neuronal excitability and synaptic plasticity78. 
 
 
1.4 Di-Guanylate Cyclases 
1.4.1 Structure and Function of Di-Guanylate Cyclases 
More than 20 years ago, the presence of cyclic 3’:5’-di-guanosine monophosphate 
(c-di-GMP) in bacteria was discovered by Ross et al.81 Since then, c-di-GMP has emerged 
as a ubiquitous second messenger in bacteria. c-di-GMP is synthesized from two GTP 
molecules by the action of di-guanylate cyclases (DGCs) and degraded by specific 
phosphodiesterases (PDEs) as indicated in Fig. 1.11. DGC and PDE activity are located in 
the GG(D/E)EF and EAL domain, respectively, which are named after highly conserved 
motifs within these domains82. EAL domain proteins degrade c-di-GMP to the linear 
intermediate pGpG which is further hydrolyzed to guanosine monophosphate (GMP) by 
so far unidentified PDEs. Apart from the EAL domain, a subgroup of the HD superfamily 
of metal-dependent phosphohydrolases, the so-called HD-GYP domain, was shown to 
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have c-di-GMP specific PDE-activity83. The HD-GYP domain has no sequence similarity to 
the EAL domain and, in contrast, readily hydrolyzes c-di-GMP to GMP. Regarding the 
different products of c-di-GMP degradation, one could speculate that pGpG is also an 
active signaling molecule providing additional complexity in cellular signaling. The 
number of GGDEF and EAL domain proteins encoded in bacterial genomes is highly 
variable ranging from none (e.g. Helicobacter pylori) to intermediate numbers (e.g. 
Escherichia coli: 19 GGDEF and 17 EAL domain proteins) up to 100 of these proteins in 
Vibrio vulnificus6. Obviously, GGDEF and EAL domain proteins are highly specific as the 
knock-outs of individual domain proteins result in distinct phenotypes despite the 
presence of other GGDEF, EAL, and/or HD-GYP domain proteins84,85. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.11 c-di-GMP metabolism (modified from Tamayo et al.86). c-di-GMP is synthesized via 
condensation of two GTP molecules by GGDEF domain di-guanylate cyclases (DGCs) and hydrolyzed 
either by EAL domain phosphodiesterases (PDEs) to the linear intermediate pGpG which is further 
hydrolyzed by other PDEs to GMP or by HD-GYP domain PDEs which directly degrade c-di-GMP to 
GMP. 
 
 Detailed analyses of structure-function relationships of GGDEF domains showed 
that they have a pronounced secondary structure conservation with adenylyl cyclases 
(ACs) resulting in an AC-like fold and a similar catalytic mechanism87. As deduced from 
the crystal structure of the response regulator PleD, the DGC domain consists of a 
five-stranded central β-sheet surrounded by helices88. For the catalytic activity of DGCs, 
an anti-parallel arrangement of two substrate-loaded domains is required. Hence, DGCs 
function as dimers. Since c-di-GMP-metabolizing enzymes are central constituents of 
signal transduction, they are part of multi-domain proteins with one or more N-terminal 
signaling/receiving domains89. A combination of GGDEF and EAL domains is a frequently 
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found domain structure: more than one-third of the GGDEF and more than half of the 
EAL domains exist in this combination. A large variety of signals regulates the activity of 
DGCs and PDEs (see Fig. 1.12). A well-known characteristic of DGCs is the strong 
product inhibition resulting from c-di-GMP binding to the I-site located in close proximity 
to the catalytic A-site. Allosteric feedback inhibition of DGCs is thought to be a general 
regulatory principle of c-di-GMP signaling in bacteria.  
 
 
Fig. 1.12 Regulation of di-guanylate cyclases (DGCs) and phosphodiesterases (PDEs) (taken from 
Römling and Simm90). (a) Phosphorylation of the receiver domain (Rec) of response regulators 
activates the DGC function of GGDEF domains. (b) Binding of c-di-GMP to the I-site of the GGDEF 
domain leads to allosteric product inhibition of DGC activity. (c) Binding of GTP to a GGDEF domain 
with degenerate GGDEF motif activates the PDE function of EAL domains. (d) Oxygen binding to the 
PAS domain inhibits the PDE A1 in Gluconacetobacter xylinus. (e) Sensing of the substrate-loaded, 
putative norspermidine-binding protein by the GGDEF-EAL domain protein MbaA in Vibrio cholerae 
reduces the ability of MbaA to inhibit biofilm formation. (f) The EAL domain protein Arr in 
Pseudomonas aeruginosa senses the antibiotic tobramycin. GAF: nucleotide/nucleoside-binding 
domain; SBP_Bac_1: solute-binding protein family 1. 
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 Environmental stimuli are transmitted by the c-di-GMP signaling network and, 
thereby, evoke specific responses of bacterial cells. So far, several direct targets for 
c-di-GMP have been identified. Particularly, the PilZ domain was the first c-di-GMP 
effector protein discovered and represents a family of c-di-GMP binding proteins 
combined with various N-terminal domains91. PilZ domains exhibit high sequence 
diversity and thus trigger diverse downstream physiological events: BcsA and YcgR are 
examples of PilZ domains representing a c-di-GMP-dependent bacterial cellulose 
synthase and a protein regulating flagellum-based motility, respectively92. The recently 
discovered PilZ domain protein PlzA from Borrelia burgdorferi is expressed during 
mammalian infection93. 
Moreover, c-di-GMP effectors other than PilZ domain proteins are being 
discovered consecutively: the transcriptional regulator FleQ94 and the regulator of 
polysaccharide biosynthesis PelD95, both encoded by Pseudomonas aeruginosa, and the 
c-di-GMP effector protein PopA96 involved in cell cycle progression have been identified 
as c-di-GMP targets. The global regulator Clp from Xanthonomas campestris which 
positively regulates virulence factor production strongly interacts with c-di-GMP97. 
Eventually, c-di-GMP was found to bind to riboswitches in the untranslated regions of 
mRNAs and thus alters the expression of downstream genes98. 
 During the last years of c-di-GMP research it has become obvious that c-di-GMP 
controls cellular functions at the transcriptional, translational and posttranslational level. 
However, researchers are just beginning to understand the complex c-di-GMP signaling 
network as accurately described by Römling and Simm: “Still, we have only scratched 
the surface in this new area of research.”90 
 
1.4.2 Formation and Characterization of Biofilms 
During the last decades, it has become clear that most bacteria predominantly exist in 
complex communities, so-called biofilms99. The formation of biofilms is strongly 
influenced by intracellular c-di-GMP concentrations. In general, high c-di-GMP 
concentrations induce the formation of biofilms, whereas low concentrations favor a 
motile, planctonic lifestyle100. Biofilms can form in an enormous number of environments 
and can colonize on both biological and non-biological surfaces101. The formation of 
biofilms is a multi-step process specifically characterized by the formation of a robust 
exopolysaccharide (EPS) matrix as indicated in Fig 1.13102. 
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Fig 1.13 Development of a biofilm (http://www.genomenewsnetwork.org/articles/06_02/biofilms 
_image1.shtml, 06-10-2010). (1) Initial attachment of planctonic cells to the surface, (2) beginning 
production of exopolysaccharide (EPS) matrix and irreversible attachment to the surface, (3) 
development of biofilm architecture, (4) maturation of biofilm matrix, and (5) dispersion of single cells 
from the biofilm. The bottom photomicrographs show the five stages of biofilm formation of 
Pseudomonas aeruginosa grown on a glass substratum. 
 
 In natural environments, biofilms usually consist of numerous different bacterial 
species each of which finds its own niche within the biofilm103. The formation of biofilms 
is based on effective cell-to-cell communication, called quorum sensing, via extracellular 
signaling molecules104. The nature of these quorum sensing or autoinducer molecules is 
thought to be very diverse. Gram-negative bacteria are known to mainly use N-acyl-L-
homoserine lactones (AHLs) to communicate with each other whereas furanosyl borate 
diesters are inter-species autoinducer molecules. Bacteria existing in robust biofilms 
cause persistent and chronic infections with inherent resistance to antibiotics105. 
Numerous human infections can be ascribed to the establishment of biofilms as indicated 
in Table 1.3. For example, the human pathogen Pseudomonas aeruginosa colonizes the 
airways of cystic fibrosis patients, thereby causing severe lung damages. Due to the 
biofilm architecture of the pathogen even long-term antibiotic therapy cannot eradicate 
the infection106. Moreover, biofilm forming bacteria can cause infections in patients with 
indwelling medical devices which is a serious problem for public health107. 
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Table 1.3 Selection of human infections involving biofilms (modified from Costerton et al.105). 
Infection or disease Common biofilm bacterial species 
Dental caries 
Periodontitis 
Otitis media 
Musculoskeletal infections 
Necrotizing fasciitis 
Biliary tract infection 
Osteomyelitis 
Bacterial prostatitis 
Native valve endocarditis 
Cystic fibrosis pneumonia 
Meloidosis 
Acidogenic Gram-positive cocci (e.g. Streptococcus) 
Gram-negative anaerobic oral bacteria 
Non-typable strains of Haemophilus influenzae 
Gram-positive cocci (e.g. staphylococci) 
Group A streptococci 
Enteric bacteria (e.g. Escherichia coli) 
Various bacterial and fungal species - often mixed 
Escherichia coli and other Gram-negative bacteria 
Viridans group streptococci 
Pseudomonas aeruginosa and Burkholderia cepacia 
Pseudomonas pseudomallei 
 
 Facing the high number of biofilm-related infections and diseases it is necessary 
to elucidate the mechanisms of antibiotic resistance of bacteria in biofilms in order to 
develop new therapies. However, researchers are just beginning to find out the exact 
mechanisms108,109. A first hypothesis deals with slow or incomplete penetration of 
antibiotics into the biofilm. The antibiotic is more rapidly deactivated in the surface layer 
than it diffuses. Hence, its delivery into the core of the biofilm is retarded. Secondly, it is 
believed that biofilms have an altered microenvironment. Apart from anaerobic niches 
which can appear due to high oxygen comsumption, pronounced pH differences between 
the bulk fluid and the biofilm interior can be produced as a cause of local accumulation 
of waste products. These extreme environments can antagonize the action of antibiotics. 
As a result of nutrient depletion, bacteria within the biofilm are also believed to enter a 
non-growing state in which they cannot be attacked by antibiotics which often target 
cell-wall synthesis. The third and most speculative hypothesis is that bacteria in biofilms 
are able to differentiate into a protected phenotypic state, so-called persisters. Yet, as 
stated by Mah and O’Toole110 “There is no one answer to the question of why and how 
bacteria growing in a biofilm develop increased resistance to antimicrobial agents.” 
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1.5 Methods for the Analysis of GTP-Converting Proteins and 
Enzymes 
The GTP-converting proteins and enzymes introduced in the previous sections are 
central constituents of specific signal transduction pathways. Since the discovery of the 
individual signaling systems, effective detection and quantitation methods for the 
respective signal molecules have been established. Facing the high complexity of signal 
transduction pathways, their detailed elucidation has challenged the scientific 
community. Today, a broad spectrum of methods for the analysis of GTP-based signaling 
systems is available. Table 1.4 provides an overview of the most applied methods and 
addresses corresponding advantages and disadvantages. 
 One of the first methods developed which is still used today, is based on 
radioactively labeled substrates ([32P]- and [33P]-labeled GTP) applied for in vitro enzyme 
assays111,112,113. Despite high sensitivity, the risks arising from the handling of radioactive 
material have led to the development of alternative methods. The introduction of 
column-chromatographic separation and purification techniques have been an important 
step resulting in the establishment of robust HPLC-UV detection methods which can be 
automated but have relatively high detection limits114,115,116. Fluorescently labeled 
nucleotides enabled the detection of the interaction of those nucleotides with specific 
proteins due to the sensitivity of fluorescent groups to their surrounding environment117. 
Coupling of HPLC separation to mass spectrometric analysis is very sensitive and allows 
simultaneous and highly specific detection and quantitation of signaling molecules118. 
Specifically for the detection of cGMP, competition-binding approaches are used: radio 
immuno assay (RIA)119 and enzyme-linked immunosorbent assay (ELISA)120. These 
techniques became available after the devolpment of specific anti-cGMP antibodies. The 
read-out is based on the detection of either radioactively labeld cGMP (RIA) or the 
products of enzymatic reactions coupled to secondary antibodies. 
 Each analysis method has distinct advantages and disadvantages for a specific 
scientific question. However, as we elucidate more and more details of GTP signaling 
networks the analytical requirements continuously increase. Hence, there still is a great 
need for the development of more sensitive, robust, and reliable detection and 
quantitation methods in this field of research. 
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Table 1.4 Detection methods for GTP-converting proteins and enzymes. HPLC: high-performance 
liquid chromatography; MS: mass spectrometry; RIA: radio immuno assay; ELISA: enzyme-linked 
immunosorbent assay DGC: di-guanylate cyclase; GC: guanylyl cyclase. 
Method Protein/enzyme Advantages (+) and disadvantages (-) 
[32P]/[33P]-
labeled 
substrates 
GTP-binding proteins112,121,122 
DGCs123,113 
GCs111,124 
+ high sensitivity 
+ direct detection of nucleotides 
- radioactivity: demanding special training/facility 
- waste disposal 
HPLC-UV 
GTP-binding proteins114 
DGCs116 
GCs115 
+ direct detection of nucleotide 
+ non-radioactive 
- low sensitivity 
- slow sample processing 
MS 
DGCs125,126,94,127 
GCs118 
+ high sensitivity 
+ high specificity 
+ direct detection of nucleotides 
- expensive equipment 
- slow sample throughput 
Fluorescence GTP-binding proteins117,128 
+ high sensitivity 
+ high sample throughput 
- derivatization necessary 
- interference with matrix components 
RIA GCs119 
+ high sensitivity 
+ high specificity 
- radioactivity: demanding special training/facility 
- laborious processing of samples prior to assay 
- cross-reactivity 
- antibody needed 
ELISA GCs120 
+ high sensitivity 
+ high specificity 
+ non-radioactive 
- expensive kits 
- cross-reactivity 
- antibody needed 
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2. Aim of Work 
Fluorescence Assay for Ras 
The development of cancer still poses a high risk for public health and concerns both 
children and adults. Most forms of cancer are very aggressive and have high morbidity 
rates. Successful therapies often depend on early recognition of the disease but at later 
stages effective treatment is difficult. The development of cancer is often characterized 
by the presence of mutated Ras proteins. In about 30% of all human tumors, mutated 
Ras oncogenes are present. Hence, much attention has been addressed to the 
elucidation of the mode of action and regulation of these small GTP-binding proteins, 
particularly with regard to the influence of various Ras regulators and their potential of 
altering Ras protein activity. A fast, simple and reliable detection method is a 
prerequisite for the examination of the effects of such regulators on Ras proteins. Hence, 
this work presents the development of a suitable, fluorescence-based in vitro assay for 
monitoring the activity of Ras protein mutants which can serve as robust platform for 
high-throughput screening experiments. 
 
HPLC-MS/MS Assay for Di-Guanylate Cyclases 
The establishment of chronic infections in different organs or tissues resulting in severe 
and partly lethal courses of disease also represents a major risk for public health. Acute 
infections often can be effectively treated by the application of antibiotics whereas 
chronic infections such as in cystic fibrosis patients are highly persistent and antibiotic 
treatment has only negligible success. Chronic infections are characterized by the 
formation of bacterial biofilms whose development is regulated by the concentration of 
the second messenger c-di-GMP. The detailed characterization of the c-di-GMP-signaling 
network is a prerequisite to understand the exact correlation of c-di-GMP concentration 
and biofilm formation. In this thesis, a very sensitive and highly specific HPLC-MS/MS 
quantification method for c-di-GMP is presented which is applicable to both in vitro and 
in vivo detection. 
 The development of effective antibiotics against biofilm formation is stagnant. Di-
guanylate cyclases (DGCs) can serve as pharmacological targets in order to interfere 
with the c-di-GMP-signaling network in bacteria, and hence, the formation of persistent 
biofilms. Thus the interaction of a DGC with possible inhibitors based on a simple 
fluorescent assay and the HPLC-MS/MS method is presented. 
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3. Kinetic Determination of the GTPase Activity of Ras 
Proteins by Means of a Luminescent Terbium Complex 
3.1 Abstract 
Guanine nucleotide binding proteins, such as Ras proteins, play a pivotal role in 
maintaining the regular life cycle of cells. The involvement of Ras mutants in the 
progress of cancer has attracted many efforts to find detection methods for Ras activity. 
In this study we present a luminescent microwell plate assay for monitoring GTPase 
activity of Ras proteins. The luminescence intensity of the Tb-norfloxacin complex is 
influenced by nucleoside phosphates as well as by inorganic phosphates. Real-time 
kinetics of the GTPase activity of wildtype Ras and Ras mutants can be monitored online. 
The effect of a GTPase activating protein as well as of a downstream effector (Ras-
binding domain of human Raf-1) on the GTPase activity of different Ras mutants is 
examined. In contrast to other methods, this assay does not require the use of 
radioactively labeled substrates or chromatographic separation steps. Moreover, the 
application of fluorescently labeled GTP substrates which often interfere with enzymatic 
activity can be avoided. This in vitro assay can serve as a model system for the 
screening of regulators affecting the GTPase activity of Ras proteins. 
 
 
3.2 Introduction 
Guanine nucleotide binding proteins of the Ras superfamily consist of several subunits 
with about 100 different proteins. One of the subunits comprises those of the so-called 
Ras (rat sarcoma) family. These proteins are central constituents of the signal 
transduction pathway, ranging from membrane receptors to downstream intracellular 
effectors, and thereby control cell growth, differentiation, and apoptosis1. Nowadays, it is 
estimated that in up to 30% of all human tumors mutated Ras oncogenes are present2. 
Ras GTPases act as binary switches by cycling between a GDP-bound “off” state and a 
GTP-bound “on” state. The intrinsic GTPase activity converts GTP to GDP and phosphate, 
the latter being released. Mg2+-GDP and Mg2+-GTP are coordinated by the active center 
of Ras in presence of an excess of Mg2+. It is essential for Ras to be localized in the 
plasma membrane in order to accomplish its biological function. Therefore, several 
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posttranslational modification processes are necessary in which lipids are covalently 
attached to the carboxy-terminus of Ras. Ras proteins interact with downstream 
effectors such as Raf (rapidly growing fibrosarcoma) in the active, GTP-bound form. 
They activate specific signaling pathways such as the mitogen-activated protein kinase 
cascade. Since the intrinsic GTPase activity is only low and the associated GDP-GTP 
exchange process is intrinsically very slow, regulatory units determine Ras activity. 
Guanine nucleotide exchange factors (GEFs) activate the inactive, GDP-bound Ras by a 
fast GDP-GTP exchange process, whereas GTPase activating proteins (GAPs) accelerate 
GTP hydrolysis3. 
 Mutated Ras proteins are widely involved in the development of cancer. This has 
aroused interest for Ras regulators as potential antitumor drugs. Mainly, four different 
approaches are pursued which aim at controlling Ras activity4,5,6: (1) Inhibition of Ras 
activation by preventing GDP-GTP exchange via GEFs, (2) deactivation of Ras by 
stimulating the intrinsic GTPase activity thereby avoiding interactions of the active, GTP 
bound form of Ras with its downstream effectors, (3) inhibition of Ras posttranslational 
modification by farnesylation, and (4) antagonizing Ras interactions with its downstream 
effectors. Hence, fast and straightforward methods for monitoring Ras activity and the 
influence of possible drugs are sought after. 
 Analytical techniques for the detection of Ras activity are based on the 
determination of the GTPase substrate and/or reaction products. Mainly, [32P]-labeled 
nucleotides are applied for Ras activity assays. After immunopurification, Ras-bound 
nucleotides are eluted and a separation of GDP/GTP by thin layer chromatography (TLC) 
is carried out7. Scintillation counting is required for quantitative analysis. This procedure 
is very prone to errors and time-consuming. A more rapid analysis of absolute GDP/GTP 
levels is achieved by using high-performance liquid chromatography (HPLC). For this 
purpose, the radioactively labeled nucleotides are eluted after immunoprecipitation of 
Ras and separated on a reversed phase C-18 column. The eluted nucleotides are 
detected online by Čerenkov counting8. 
 The GDP/GTP ratio can also be accessed by direct UV absorption of the 
nucleotides after HPLC separation with preceding denaturation of Ras as presented in 
“Materials and Methods”. This method renders the use of labeled nucleotides redundant 
but is limited in terms of time resolution. Other non-radioactive techniques have been 
described which take advantage of the higher affinity of the Ras-binding domain (RBD) 
of Ras-effectors for the active, GTP-bound conformation of Ras9,10. A recombinant RBD is 
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added to cell extracts, thereby precipitating only Ras-GTP owing to a three orders of 
magnitude higher affinity compared to Ras-GDP. Ras is detected by Western blotting. 
However, this method can only reflect semi-quantitative results due to the high number 
of experimental steps necessary. 
 Moreover, fluorescent guanine nucleotide derivatives, namely 3’-O-(N-
methylanthraniloyl (MANT)11 and boron-dipyrromethene (BODIPY)12 have been 
developed. MANT has been used for investigating basal and GAP-stimulated GTPase 
activity13,14,15 as well as for studying interactions with GEFs16,17 and effectors18,19,20 
whereas BODIPY was applied to Ras-like proteins to monitor guanine nucleotide 
exchange21,22. These approaches demonstrate the importance of fluorescence analysis 
and underline the efforts made in designing fluorescent probes for particular 
applications. Since fluorescence is very sensitive, many probes have been and still are 
being developed, especially for nucleoside phosphates and inorganic phosphates, which 
are most ubiquitous in biological systems. While numerous fluorescent probes for 
phosphate and pyrophosphate as well as for adenine nucleotides are available23, probes 
for guanine nucleotides are rather rare24. Most probes cannot be used under 
physiological conditions which restricts their applicability. 
 Various lanthanide complexes have been reported to respond to phosphates 
and/or nucleotides, particularly Eu3+ 25,26,27 and Tb3+ 28,29 chelates. The great interest in 
lanthanide ions originates from their distinct spectral properties, such as line-like 
emission, long luminescence lifetime and a large Stokes shift. Most often, so-called 
antenna ligands are used for the coordination to overcome the small absorptivity of the 
ions themselves. The use of the pure lanthanide ion as a luminescent probe is rather 
rare30. A non-radiative energy transfer from the excited organic ligand to the central 
lanthanide ion results in a long wave emission although the complex is excited in the UV. 
Tb3+-norfloxacin (Tb-Nflx) (with a stoichiometry of 4.5:1) was reported to respond to 
ATP by a strong luminescence enhancement31. The effect of different nucleotides as well 
as of phosphate and pyrophosphate was examined and an assay for the determination of 
adenylyl cyclase activity was established32,33. No interferences occur upon addition of 
physiological levels of Ca2+ and Mg2+ or other proteins. 
 In this work, the response of Tb-Nflx to GTP, GDP and Pi was used to set up an 
assay for GTPase activity. We used Tb-Nflx as luminescent probe to monitor Ras activity 
at an emission wavelength of 545 nm. Thereby, the release of phosphate due to 
hydrolysis of GTP is indicated in real-time by means of luminescence quenching. The 
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kinetics of several Ras mutants with different activities are compared and evaluated by 
the determination of hydrolysis constants khyd. The influence of both a GAP and a 
downstream effector (RBD of human Raf-1, Raf-RBD) on the activity of different mutants 
of Ras proteins can be monitored with this method. 
 
 
3.3 Materials and Methods 
3.3.1 Protein Purification 
Wildtype proteins of human H-Ras [Ras(wt)] and mutant proteins of human H-Ras 
(amino acids 1 to 189) were expressed in Escherichia coli and purified as described 
before34. The final purity of the protein was > 95% as judged by sodium dodecyl sulfate 
polyacrylamid gel electrophoresis. Nucleotide exchange to GTP was performed 
incubating 200 µM of Ras with 50 mM tris(hydroxymethyl)aminomethane (pH 7.5), 
30 mM EDTA, 10 mM GTP, and 2 mM 1,4-dithioerythritol for 5 h or 18 h at 5 °C. 
Afterwards, EDTA and free nucleotides were completely removed by gel filtration. The 
concentration of active nucleotide bound Ras was determined via the nucleotide 
concentration by C18-reversed phase chromatography using 100 mM K2HPO4/KH2PO4 
pH 6.5/10 mM tetrabutyl-ammonium bromide/7% (v/v) acetonitrile as the buffer and a 
calibrated detector system. Finally, 80-85% of Ras was bound to GTP and 15-20% to 
GDP. Raf-RBD (amino acids 51 to 131) was expressed in Escherichia coli and purified as 
described before35. Neurofibromin 1-333 was expressed as glutathione-S-transferase 
fusion protein, followed by the cleavage using thrombin on a glutathione-Sepharose 
column. Afterwards, a gel filtration step was performed to remove the protease. 
 
3.3.2 Microwell Plate-Based Luminescence Assay 
Luminescence intensities (time-resolved) were acquired by using a BMG FLUOstar 
OPTIMA microplate reader (Jena, Germany). The excitation/emission filters were set to 
337 and 545 nm, respectively. All dilution series and calibration plots were obtained in 
96-microwell plates with four replicates. Enzyme assays were performed with 3 
replicates applying time-gated detection at a time lag of 60 µs after the excitation pulse 
and a signal-integration time of 60 µs. For detailed description of time-gated 
measurements see Ref. 36. All experiments were performed at 37 °C, unless otherwise 
stated. The 96-microwell plates were obtained from Greiner Bio-One (Frickenhausen, 
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3.3.3 Reagents 
All chemicals were of analytical grade. Magnesium dichloride hexahydrate and tri-
sodiumphosphate dodecahydrate were purchased from Merck (Darmstadt, Germany). 
Bovine serum albumin (BSA) (≥ 96%, essentially fatty acid free), TbCl3·6H2O, 
norfloxacin, guanosine-5´-triphosphate sodium salt hydrate (≥ 95%, HPLC), guanosine-
5’-diphosphate sodium salt (≥ 96%, HPLC) and 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) (≥ 99.5 % titration) were obtained from Sigma-Aldrich 
Chemie (Steinheim, Germany). 
 Buffered solutions contained 40 mM HEPES at pH 7.4. Tb-Nflx solutions contained 
100 µM TbCl3·6H2O and 22.22 µM norfloxacin. The ratio Tb3+ to norfloxacin was 4.5:1 as 
reported in the literature. A 100 µM norfloxacin solution was prepared by dissolving 
norfloxacin in a small amount of 1 mM hydrochloric acid followed by dilution with HEPES-
buffered solution to the appropriate volume. Five hundred microliters of a 1 mM Tb3+ 
solution and 1,111 µL of a 100 µM norfloxacin solution were combined and made up to 
5 mL. The amount of Tb-Nflx in solution is represented by the concentration of Tb3+. 
 
3.3.4 Enzyme Activity Assay 
The assays were recorded in 96-well microplates with each well containing a final 
volume of 100 µL at final concentrations of 0.5 mM Mg2+ and 0.1 % (m/v) BSA. The Tb-
Nflx concentration was 20 µM (relating to Tb3+). The amount of Ras added to the single 
kinetics is represented by the corresponding GTP concentration which is determined 
subject to the extent of GTP loading of each Ras mutant. Hence, all kinetics are referred 
to the initial GTP rather than the initial Ras concentration. Initial GTP concentrations 
were varied from 6 to 24 µM. 
 The effect of neurofibromin 1 (NF1) on the enzyme kinetics was examined by 
adding 4 µL of a 1:10 diluted NF1 stock solution to each well, independent of the applied 
enzyme concentration resulting in a high stoichiometric deficiency of NF1 compared to 
Ras of roughly 1:100. Raf-RBD was added in a 1.5 molar excess compared to the initial 
GTP concentration used. 
 The assay solution was incubated at 37 °C for 30 min before the addition of Ras 
proteins and their additional regulators, all of which were stored on ice until their 
addition to the assay solution. After addition of the enzyme, the measurements were 
started immediately. 
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3.4 Results 
3.4.1 Calibration Plots for Guanine Nucleotides, Inorganic Phosphate, and 
GTPase Reaction 
The luminescence spectrum of Tb-Nflx has been presented previously31. This assay used 
the change in intensity of the Tb3+ main emission band at a wavelength of 545 nm which 
corresponds to the 5D4  7F5 electronic transition. The ligand was excited at 337 nm 
throughout all experiments. The effect of GTP, GDP and inorganic phosphate on the 
emission of the complex is displayed in Fig. 3.1. The concentration of Tb-Nflx was kept 
constant at 20 µM (relating to Tb3+) throughout, unless otherwise stated. GDP and GTP 
had different effects on the emission intensity. GDP enhanced the luminescence more 
than twofold, whereas GTP induced only a weak increase of about 30%. Phosphate 
quenched the emission of Tb-Nflx to 10% of its initial value. All three ligands seemed to 
form a 1:1 complex with Tb3+. Tb-Nflx was able to clearly discriminate between GDP and 
GTP. This was in contrast to ADP and ATP which both induced the same luminescence 
enhancement of Tb-Nflx32. This turned Tb-Nflx into a promising probe for monitoring 
GTPase activity which converts GTP to GDP and phosphate. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1 Normalized luminescence intensity I/I0 of the Tb-Nflx complex (20 µM) in presence of various 
concentrations of GDP (squares), GTP (circles) and phosphate (triangles) at 25 °C. The single 
response curves are fitted sigmoidally. Error bars are standard deviations of the mean. 
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Scheme 3.1 Enzymatic conversion of GTP to GDP and phosphate (Pi) by Ras accompanied by a 
significant decrease in lanthanide luminescence of Tb-Nflx due to strong quenching by Pi. ER: 
enzymatic reaction. 
 
 In the course of the GTPase reaction of Ras proteins, GTP is converted to GDP 
and phosphate (Scheme 3.1). GDP remains bound to Ras, whereas phosphate is 
released. The specific response of Tb-Nflx to phosphate under assay conditions (see 
“Materials and Methods”) is illustrated in Fig. 3.2. The referenced emission signal 
decreased with increasing phosphate concentration until it reached a constant level of 
about 0.15 at a phosphate concentration of 20 µM. This indicated the formation of a 1:1 
complex also under assay conditions. The linear range was between 1 and 12 µM of 
phosphate at a Tb-Nflx concentration of 20 µM. 
 
 
 
 
 
 
 
 
 
Fig. 3.2 Normalized luminescence intensity I/I0 of the Tb-Nflx complex (20 µM) with sigmoidal fit in 
presence of phosphate under assay conditions (see “Materials and Methods”). Error bars are standard 
deviations of the mean. 
 
3.4.2 Monitoring of GTPase Reaction 
Ras(wt) served as model enzyme for the GTPase assay. Prior to recording the different 
kinetics, we added inactive, GDP-bound Ras(wt) [Ras(wt):GDP] to Tb-Nflx to assess 
unspecific interactions of the protein with the lanthanide complex. Its luminescence 
emission was only slightly enhanced in presence of increasing Ras(wt):GDP 
concentrations. After an addition of 25 µM Ras(wt):GDP, an increase of only 15% was 
detected. This unspecific luminescence enhancement can be induced by interactions of 
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nucleophilic groups (e.g. hydroxyl, carboxylic acid or thiol groups) in the amino acid side 
chains on the outer surface of the Ras protein with the terbium ion. However, this weak 
unspecific interference of Ras with the luminescence of Tb-Nflx was not significant since 
all data were referenced as I/I0, where I0 represents the luminescence intensity at t=0 
directly after addition of Ras. 
 The Ras(wt) protein was loaded with GTP [Ras(wt):GTP]. Its intrinsic GTP 
hydrolysis activity was enhanced with increasing temperature, and was measured at 
37 °C throughout all experiments. GTP was converted to GDP which remained bound to 
Ras(wt) and phosphate was released. GEFs or GAPs were not used because the intrinsic 
activity of Ras(wt) at a concentration of 25 µM was sufficient to be monitored in the 
assay within a reasonable timescale. A 30 minute tempering of the assay solution at 
37 °C was necessary prior to the addition of Ras(wt):GTP to ensure a stable emission 
signal of the lanthanide complex which exhibited a significant thermal quenching effect. 
The luminescence intensity of Tb-Nflx was decreased by 30% when the temperature of 
the sample solution was raised from 25 to 37 °C. The emission of Tb-Nflx at 545 nm 
decreased after addition of Ras(wt):GTP to the assay mixture (Fig. 3.3). Ras was stored 
at 4 °C prior to the addition. The rate of decrease was dependent on the initial GTP 
concentration. All kinetic measurements were referred to the initial GTP concentration 
and not to the specific enzymatic activity of Ras because it was not possible to 
completely load the Ras samples with GTP. The luminescence response of Tb-Nflx to 
phosphate was one order of magnitude faster than the timescale of the enzyme kinetics. 
Therefore, real-time kinetics of the intrinsic GTPase activity of Ras were recorded. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3 Kinetics of different concentrations of initial GTP in wildtype protein of human H-Ras 
[Ras(wt)]: 6 µM (open circles), 12 µM (closed triangles), 15 µM (open squares), 18 µM (closed 
circles), 24 µM (open triangles), and Tb-Nflx (20 µM) as a reference (closed squares). Error bars are 
standard deviations of the mean. 
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 The kinetics of Ras(wt):GTP displayed in Fig. 3.3 required referencing to the initial 
GTP concentration in order to assess the specific hydrolysis constant (khyd). A slight shift 
in the reference signal occured in the first minutes due to temperature effects that had 
an impact on the luminescence of the probe as indicated by the reference in Fig. 3.3. 
After about 20 to 25 minutes the reference signal had stabilized. Thus, khyd was 
determined in a subsequent time period from 25 to 50 minutes: The absolute value of 
the slope of the linear range between 25 and 50 minutes of each kinetic trace was 
divided by the corresponding initial GTP concentration according to Equation 1. The 
extent of GTP loading of the individual Ras mutants differed owing to the preparation 
procedure of the Ras:GTP complex. Only by applying the same initial GTP concentration, 
it was feasible to compare different kinetic runs. Hence, it was favored to calculate a 
specific hydrolysis constant by referencing to the initial GTP concentration and not to the 
associated amount of enzyme. An average specific hydrolysis constant of 
360 ± 116 L/(min mol) was determined for Ras(wt):GTP. 
 
   
[ ]
( ) [ ]mol/L GTPc
1/min slope
khyd =   Equation 1 
 
 The kinetics of Ras(wt):GTP were compared with those of several Ras mutants 
with different GTPase activities, namely, Ras(T35S):GTP, Ras(Y32R):GTP, and the 
oncogene Ras(G12V):GTP. The GTPase activity decreased in the following order: 
Ras(Y32R):GTP > Ras(wt):GTP > Ras(T35S):GTP > Ras(G12V):GTP (Spoerner M, 
Hosza C, Poetzl J, Reiss K, Ganser P, and Kalbitzer HR, unpublished results). The shape 
of the kinetic traces of GTP hydrolysis for Ras(Y32R):GTP and Ras(T35S):GTP were 
comparable to those of Ras(wt):GTP (Fig. 3.4), while the slopes between 25 and 
50 minutes varied due to the different intrinsic GTPase activities. GTP hydrolysis by 
Ras(G12V):GTP was very slow. Hence, only a slight decrease of the emission signal was 
observed even when using high initial GTP concentrations. Ras(G12V):GTP activity was, 
therefore, not evaluated by the calculation of khyd but served as negative control of an 
inactive Ras mutant. The active Ras mutants had different activities but in all cases the 
same referenced emission signal level (I/I0 ~ 0.2) was obtained after 200 minutes. This 
coincided with the use of the same initial GTP concentration and, hence, the same 
amount of released phosphate. This had to be accompanied by an identical endpoint of 
the luminescence decrease for each Ras mutant. Furthermore, the final emission signals 
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of the various kinetic determinations agreed with the signal obtained from the calibration 
plot (see Fig. 3.2) at a phosphate concentration of 18 µM. Hence, instead of I/I0 the 
calculated concentration of released phosphate can be plotted versus time. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4 Kinetics of Ras(G12V):GTP (open circles), Ras(T35S) (triangles), Ras(wt):GTP (open 
squares), and Ras(Y32R):GTP (closes circles) at an initial GTP concentration of 18 µM and Tb-Nflx 
(20 µM) as a reference (closed squares). Error bars are standard deviations of the mean. 
 
 Table 3.1 compares the calculated specific hydrolysis constants of the Ras 
mutants at an initial GTP concentration of 18 µM. Ras(T35S):GTP displayed a smaller khyd 
compared with Ras(wt):GTP, while Ras(Y32R):GTP had a higher khyd than expected. The 
GTPase activity of the different Ras mutants was monitored at several initial GTP 
concentrations as illustrated above for Ras(wt):GTP. The standard deviations obtained 
had the same dimension as presented for Ras(wt):GTP. However, for some kinetic runs 
the khyd values may deviate to a greater extent, particularly in case of lower Ras:GTP 
concentrations. Thus, it was important to define standard conditions for the comparison 
of different Ras mutants and the potency of regulators. The use of approximately 
equimolar amounts of initial GTP to Tb3+ is recommended as maximum quenching was 
obtained in case of a 1:1 complex of Tb3+ with phosphate (Fig. 3.2). For this reason, 
only kinetics at an initial GTP concentration of 18 µM are presented exemplarily in the 
following, even though they were also recorded for different concentrations from 6 to 
24 µM. Table 3.1 shows that it was possible to monitor GTP hydrolysis by Ras proteins 
due to the detection of phosphate release by Tb-Nflx. The activities of different Ras 
mutants were accessible by means of the determination of hydrolysis constants derived 
from the linear range of the kinetics. The stated hydrolysis constants are mean values 
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from three separate kinetic runs. Standard deviations of around 20% for all selected Ras 
mutants were found. 
 The conditions of the assay had to be chosen carefully. The dynamic range for 
phosphate determination by Tb-Nflx was strongly dependent on the concentration of the 
probe, because phosphate undergoes 1:1 binding with Tb3+ as can be deduced from 
Fig. 3.1. The same initial GTP concentration using Ras(wt):GTP can result in a 
completely different extent of quenching at different Tb3+ concentrations. 
 
Table 3.1 Hydrolysis constants (khyd) (L/(min mol)) for different Ras mutants at an initial GTP 
concentration of 18 µM. 
 Ras(wt):GTP Ras(T35S):GTP Ras(Y32R):GTP Ras(G12V):GTP 
khyd 353 ± 88 257 ± 58 398 ± 54 Inactive 
 
 
3.4.3 Effect of GAP and Raf-RBD on Ras Activity 
The GTPase activity of Ras proteins is regulated by GAPs and/or GEFs. Furthermore, 
active, GTP-bound Ras proteins interact with downstream effectors and thereby initialize 
signaling cascades. In this assay, the effect of a GAP (NF1) and a downstream effector 
(Raf-RBD) on the GTPase activity of various Ras mutants was investigated. In the 
following the influence of NF1 and/or Raf-RBD on Ras mutants is exemplarily presented 
for an initial GTP concentration of 18 µM, throughout. 
 NF1 is known to increase the activity of Ras(wt) and of Ras(T35S)37. The kinetics 
of Ras(wt):GTP and Ras(T35S):GTP in presence of NF1 are shown in Figs. 3.5a and b. In 
case of Ras(wt):GTP, the GTP hydrolysis was completed within about 75 minutes in 
presence of NF1 as indicated by the constant emission signal of 0.25. The signal without 
NF1, however, reached the same level only after 200 minutes. The Ras(T35S):GTP 
kinetics also displayed higher GTPase activity after addition of NF1 compared with the 
kinetics without GAP. GTP hydrolysis was almost complete after about 50 minutes. The 
increase of Ras activity was evaluated by the determination of khyd as introduced earlier 
(see Equation 1). khyd values were higher in presence of NF1 for both Ras(wt):GTP and 
Ras(T35S):GTP as indicated in Table 3.2. 
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Fig. 3.5 Kinetics of various Ras mutants at an initial GTP concentration of 18 µM in presence of 
different regulators with Tb-Nflx (20 µM) as a reference (squares). (a) Ras(wt):GTP and (b) 
Ras(T35S):GTP in absence (circles) and presence (triangles) of neurofibromin 1 (NF1), (c) 
Ras(T35S):GTP and (d) Ras(Y32R):GTP in absence (circles) and presence (triangles) of the Ras-
binding domain of human Raf-1. Error bars are standard deviations of the mean. 
 
Table 3.2 Hydrolysis constants (khyd) (L/(min mol)) for different Ras mutants in presence of 
neurofibromin 1 (NF1) or the Ras-binding domain of human Raf-1 (Raf-RBD) at an initial GTP 
concentration of 18 µM. 
Ras-binding protein Ras(wt) Ras(T35S) Ras(Y32R) 
- 
NF1 
Raf-RBD 
353 
446 
- 
257 
801 
411 
398 
527 
6,167a 
 
a Calculated between 0 and 5 minutes 
 
 To examine the influence of a downstream effector on Ras activity we used Raf-
RBD. Downstream effectors usually do not alter the GTPase activity of Ras proteins. 
However, the rate of GTP hydrolysis can be accelerated in mutated forms of Ras(wt). 
Figs. 3.5c and d show the kinetics of Ras(T35S):GTP and Ras(Y32R):GTP in absence and 
presence of Raf-RBD. GTP hydrolysis by Ras(T35S):GTP after addition of Raf-RBD was 
complete after 100 minutes, whereas it only took about 25 minutes in case of 
Ras(Y32R):GTP which was strongly effected by Raf-RBD. The khyd values in presence of 
Raf-RBD are given in Table 3.2 and were higher compared with khyd without the effector 
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for both Ras(T35S):GTP and Ras(Y32R):GTP. The specific hydrolysis constant of 
Ras(Y32R):GTP was calculated between 0 and 5 minutes due to the extremely fast GTP 
hydrolysis in presence of Raf-RBD resulting in a complete turnover after 25 minutes. 
 It is known that neither NF1 nor Raf-RBD effects the activity of Ras(G12V):GTP 
and that Raf-RBD as a downstream effector does not alter the GTPase activity of 
Ras(wt):GTP (Spoerner M, Hosza C, Poetzl J, Reiss K, Ganser P, and Kalbitzer HR, 
unpublished results). The selectivity of NF1 and/or Raf-RBD for certain Ras mutants and 
the corresponding increase of GTPase activity was examined by performing negative 
control kinetic experiments. The effect of NF1 and Raf-RBD on Ras(G12V):GTP was 
examined in separate kinetic runs. Both Ras binding proteins did not alter the GTPase 
activity of Ras(G12V):GTP. Furthermore, Raf-RBD did not influence the activity of 
Ras(wt):GTP (results not shown). These results confirm the selective effects of NF1 and 
Raf-RBD for specific Ras mutants (Fig. 3.5) and underline the applicability of this assay 
to investigate the influence of various regulators on different Ras mutants. 
 Ras(Y32R):GTP is activated by Raf-RBD as presented above, but it is not known 
so far whether its activity can be influenced by NF1. Fig. 3.6 shows that NF1 increased 
the GTPase activity of Ras(Y32R):GTP. GTP hydrolysis was completed within 75 minutes 
in presence of NF1. Hence, this assay reveals for the first time that NF1 has an activating 
effect on the Ras(Y32R):GTP mutant. This was confirmed by the determination of a 
corresponding khyd value of 527 L/(min mol) which was higher than in absence of NF1 
with 398 L/(min mol)). Thus, this assay indicates the enhancement of Ras(Y32R):GTP 
and Ras(T35S):GTP activity by both NF1 and Raf-RBD. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 Kinetics of Ras(Y32R):GTP in absence (circles) and presence (triangles) of neurofibromin 1 
(NF1) at an initial GTP concentration of 15 µM and Tb-Nflx (20 µM) as a reference (squares). Error 
bars are standard deviations of the mean. 
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3.5 Discussion 
The routinely applied radioassays for the monitoring of enzymatic activity have the 
obvious disadvantages of handling harmful radioactive material including expensive 
waste disposal and the risk for the lab personal. Moreover, the assays are rather 
complex, and require chromatographic separation steps. However, the well established 
precipitation assay using a charcoal suspension is very sensitive and is successfully 
applied to the detection of the GTPase activity of heterotrimeric GTP-binding proteins38. 
For other non-radioactive assays, often complex immunoprecipitation steps are 
necessary. None of these detection methods enable a direct online monitoring of GTPase 
activity. The luminescent assay presented here allows for the first time the determination 
of real-time kinetics by rapid detection of phosphate released by GTP hydrolysis. 
However, the assay requires large amounts of protein which are not always easy to 
access. The assay can be easily applied to a microplate format which paves the way for 
the simultaneous performance of multiplex kinetic experiments under identical 
conditions. The microplate format enables the effect of various effectors and/or 
activators to be screened in parallel with short analysis times and at low costs. 
 The presented luminescent assay offers the possibility of examining the impact of 
newly discovered regulators on the GTPase activity of Ras proteins and/or their GAPs, 
GEFs, and downstream effectors. Moreover, the effect of Ras regulators (GAPs, GEFs, 
downstream effectors) on various Ras mutants can be investigated in a high-throughput 
manner. This study revealed that also NF1, a GAP, further stimulates the GTPase activity 
of the Ras(Y32R):GTP mutant. 
 It is aimed to extend this assay by the addition of GEFs. This will allow the 
introduction of Ras:GDP to the assay in the place of Ras:GTP. In this case, the reaction 
is started by activation of inactive, GDP bound Ras by GEFs via a fast GDP-GTP exchange 
process. Thereby, the change of the ratio between GTP and GDP/phosphate in the 
course of the GTPase reaction can be monitored. 
 
 
3.6 Conclusion 
In this study, we demonstrated the application of the Tb-Nflx complex as luminescent 
probe for the monitoring of GTPase activity of Ras proteins. The different activities of 
Ras(wt) and the mutants Ras(G12V), Ras(T35S), and Ras(Y32R) were detected in a 
straightforward microwell plate assay. Hydrolysis constants for these different Ras 
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mutants were determined. Furthermore, the effects of NF1 and Raf-RBD on the GTPase 
activity of these Ras mutants were evaluated. The determination of the corresponding 
hydrolysis constants enables the comparison of GTPase activities in absence and 
presence of GAP or downstream effectors. It was shown that Tb-Nflx is a sensitive probe 
for various nucleoside phosphates and inorganic phosphates. Its robustness and 
tolerance towards various cationic cofactors and other proteins such as BSA allows the 
adjustment to appropriate reaction conditions required for this kind of enzyme. This 
assay is cheap, straightforward, and fast to accomplish. 
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4. A Liquid Chromatography-Coupled Tandem Mass 
Spectrometry Method for Quantitation of Cyclic Di-
Guanosine Monophosphate 
4.1 Abstract 
Cyclic 3’:5’-di-guanosine monophosphate (c-di-GMP) represents an important ubiquitous 
second messenger in bacteria. It controls the transition between a sessile and a motile 
lifestyle of bacteria and, hence, affects the formation of biofilms which are highly 
resistant to antimicrobial treatment. c-di-GMP is synthesized by di-guanylate cyclases 
(DGCs) and degraded by specific phosphodiesterases (PDEs), two highly abundant 
protein families in bacteria. We have established a robust, and highly sensitive high 
performance liquid chromatography-coupled tandem mass spectrometry (HPLC-MS/MS) 
based method for the quantitation of c-di-GMP and investigated various method 
performance parameters such as limit of detection (LOD), lower limit of quantitation 
(LLOQ), linearity, accuracy, recovery and analyte stability. As a proof of principle we 
used this method to accurately measure the activity of the prototype DGC PleD* from 
Caulobacter crescentus in vitro. In addition, the new HPLC-MS/MS method was 
successfully applied to determine in vivo levels of c-di-GMP in bacterial extracts of 
Escherichia coli at different stages of bacterial growth. This demonstrates that our 
method is suitable for the sensitive and specific quantitation of c-di-GMP in bacterial cell 
extracts. 
 
 
4.2 Introduction 
Second messengers function as universal signaling molecules and play a pivotal role in 
processing extracellular information. Cyclic 3’:5’-di-guanosine monophosphate 
(c-di-GMP), originally reported as a positive allosteric regulator of cellulose synthase in 
Gluconacetobacter xylinus1, has emerged as a ubiquitous bacterial second messenger in 
the last two decades. c-di-GMP affects bacterial physiology by binding to a number of 
specific c-di-GMP binding effector components. Specifically, the PilZ domain was 
discovered as the first c-di-GMP effector2. Furthermore, the transcription factor FleQ and 
the putative inner membrane protein PelD from Pseudomonas aeruginosa3 as well as the 
4. Quantitation of c-di-GMP by HPLC-MS/MS 53 
newly discovered protein PopA from Caulobacter crescentus4 were shown to act as 
c-di-GMP effectors. Finally, c-di-GMP binding to a class of riboswitches found in the 
untranslated regions of different mRNAs in several bacterial species was reported to 
induce structural changes which alter the expression of downstream genes5. Thus, 
despite the low number of identified c-di-GMP target structures, it has already become 
clear that c-di-GMP controls cellular functions at the transcriptional, translational and 
posttranslational level. 
 c-di-GMP is produced via the condensation of two GTP molecules and hydrolysed 
to GMP via the linear intermediate pGpG. The synthesis and degradation of c-di-GMP is 
regulated by di-guanylate cyclases (DGCs) and phosphodiesterases (PDEs), respectively. 
DGCs harbor GGDEF domains while PDEs contain EAL domains6,7. These c-di-GMP-
metabolizing proteins are widely distributed in eubacteria, and in most cases, a single 
bacterial genome encodes many different members of these protein families8. c-di-GMP 
levels regulate the transition from a motile, planctonic lifestyle to a sessile, biofilm-
forming state in numerous bacterial species (for review see Ref. 9). Biofilms are 
adherent bacterial communities which can be formed on biotic and abiotic surfaces, 
including human tissues. This results for example in chronic infections by Pseudomonas 
aeruginosa in the airways of patients with cystic fibrosis10. Biofilms are highly resistant to 
antibiotic treatment and therefore contribute to bacterial persistence in chronic 
infections.  
 The enzymatic function of proteins involved in c-di-GMP metabolism and biofilm 
formation has been revealed by in vitro biochemical analyses. However, in vitro assays 
cannot give any insight in the in vivo cellular c-di-GMP levels due to the high number of 
c-di-GMP metabolizing enzymes encoded by a single bacterial genome. Thus, there is a 
need for the establishment of a reliable quantitation method for c-di-GMP in bacteria. 
 Analytical techniques for the detection of c-di-GMP usually aim at the assessment 
of either in vitro DGC- and PDE-activities or at the determination of in vivo levels of 
c-di-GMP in bacterial extracts. Frequently, [33P]- or [32P]-labeled nucleotide substrates 
are applied for both DGC11,12 and PDE13,14 activity assays. The reaction products are 
subsequently separated by thin-layer chromatography (TLC) and quantified via the 
radioactive intensities of the resulting spots. PDE assays require complex enzymatic 
synthesis and chromatographic purification of the radioactively labeled c-di-GMP 
substrate which is not commercially available. 
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 The ratio of substrate to product can also be assessed by direct UV absorption at 
254 nm after HPLC separation7. This method avoids the use of radioactively labeled 
substrates but suffers from low sensitivity and requires good peak separation. 
 The amount of c-di-GMP after nucleotide extraction from bacterial cell cultures 
can commonly only be determined in DGC overexpression studies15 and, therefore, does 
not relate to in vivo c-di-GMP levels responsible for phenotypic characteristics. Low 
c-di-GMP concentrations can be determined using mass spectrometry methods which 
often provide sufficient sensitivities. Recently, c-di-GMP concentrations in bacterial 
species have been measured by matrix-assisted laser desorption/ionization-time-of-flight 
(MALDI-TOF) mass spectrometry16. However, this method requires an elaborate 
chromatographic work-up step prior to the sample preparation for the final MALDI-TOF 
analysis and suffers from a poor linearity range. 
 Some high performance liquid chromatography-coupled tandem mass 
spectrometry (HPLC-MS/MS) based methods for the quantitation of c-di-GMP levels have 
been reported17,3,18. However, these methods exhibit various limitations, i.e. long 
analysis time, lack of internal standard, or inadequate validation. 
 The biochemical analysis of enzymes and the determination of in vivo c-di-GMP 
levels in bacteria require the establishment of a reliable and sensitive quantitation 
method in order to better understand the connection between c-di-GMP metabolism and 
the corresponding physiological output. In this report, we present the development and 
validation of a new HPLC-MS/MS method for the sensitive quantitation of c-di-GMP 
following a suitable nucleotide extraction procedure. The method was evaluated by 
measuring the in vitro activity of the constitutively active DGC PleD*. Application of the 
method to monitor the change of c-di-GMP concentration along the growth curve of 
Escherichia coli revealed that this bacterium displays increased c-di-GMP levels in 
stationary phase. 
 
 
4.3 Materials and Methods 
4.3.1 Chemicals 
Solvents used for extraction and in HPLC analysis were water, methanol and acetonitrile 
(HPLC-gradient grade, J. T. Baker, Deventer, The Netherlands). Isopropyl β-D-1-
thiogalactopyranoside (IPTG), ammonium acetate, bovine serum albumin (BSA) and 
guanosine 5’-triphosphate (GTP) were purchased from Sigma Aldrich (Steinheim, 
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Germany), sodium hydroxide, tris(hydroxymethyl)-aminomethane and magnesium 
chloride hexahydrate were obtained from Merck (Darmstadt, Germany) and acetic acid 
was from Riedel-de Haen (Hannover-Seelze, Germany). Ammonium acetate and acetic 
acid were added to the aqueous eluent A. Cyclic 3’:5’-di-guanosine monophosphate 
(c-di-GMP) was kindly provided by BioLog (Bremen, Germany) and cyclic 3’:5’-xanthosine 
monophosphate (cXMP), used as internal standard, was from Sigma Aldrich (Steinheim, 
Germany). c-di-GMP, cXMP and GTP were used in aqueous stock solutions at a 
concentration of 0.1 mg/mL, 1 mg/mL and 13 mg/mL, respectively, and stored at -20 °C. 
 
4.3.2 Expression and Purification of PleD* 
BL21(λDE3)pLys cells carrying the His6-pleD* expression plasmid were grown in LB 
medium supplemented with ampicillin (100 µg/mL) and chloramphenicol (80 µg/mL). 
Expression was induced by the addition of isopropyl 1-thio-β-D-galactopyranoside 
(0.5 mM) for 3 hours at 25 °C. Cells were harvested by centrifugation, resuspended in 
lysis buffer (10 mM Tris-HCl at pH 7.9, 300 mM NaCl, 10 mM benzamidine, 0.5 mM 
phenylmethanesulphonylfluoride, 10 µg/mL leupeptine, 5 mM imidazole) and lysed by 
passage through a French press cell. The resulting suspension was clarified by 
centrifugation (13.000 x g). The supernatant fluid was loaded onto Ni-NTA affinity resin 
(HiTrap Chelating HP, GE Healthcare, Munich, Germany), washed with starting buffer 
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and high-salt buffer (50 mM 
NaH2PO4, 500 mM NaCl, 20 mM imidazole, pH 8.0) and eluted with elution buffer 
(50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0). Eluted fractions were 
examined for purity by SDS-PAGE and fractions containing pure protein were pooled. 
Desalting and buffer exchange were performed on a Sephadex G-25 column (PD-10 
Desalting, GE Healthcare, Munich, Germany). Final protein concentration was determined 
with a Bradford assay (Carl Roth, Karlsruhe, Germany). 
 
4.3.3 Di-Guanylate Cyclase Assay 
The standard reaction mixture contained 50 mM Tris-HCl, pH 7.8, 10 mM MgCl2, 
0.1% (m/v) BSA and 100 µM GTP in a 1.5 mL volume at 30 °C. The assay was initiated 
by addition of 100 nM PleD*. Aliquots (70 µL) were withdrawn at different time points 
and the enzymatic reaction was stopped by heating to 95 °C for 5 minutes. The 
suspension was then centrifuged at maximum speed (20.000 x g) for 5 minutes in order 
to pellet denatured protein. The supernatant fluid was analyzed by reversed phase-
HPLC-MS/MS. Assays were performed in triplicate. 
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4.3.4 Extraction of c-di-GMP 
Escherichia coli K-12 wildtype MG1655 was cultivated in TB-medium at 37 °C with 
aeration. Cells were harvested (5 mL culture volume) at the indicated optical density 
(OD600) by quick centrifugation at 4 °C and the resulting cell pellet was extracted 
immediately. 
 The nucleotide extraction method reported by Rabinowitz and Kimball19 was 
modified for the extraction of c-di-GMP. The extraction solvent was a mixture of 
acetonitrile/methanol/water (40/40/20, v/v/v). The cell pellet was resuspended in 300 µL 
of ice-cold extraction solvent containing the internal standard cXMP to quench 
metabolism and initiate the extraction process followed by a 15 minutes incubation step 
at 4 °C. The cell suspension was then heated to 95 °C for 10 minutes. After cooling, the 
suspension was centrifuged at maximum speed (20.000 x g) for 5 minutes in order to 
separate insoluble material from the extracted nucleotides. The extraction of the 
resulting pellet was repeated twice with 200 µL of extraction solvent (without cXMP) at 
4 °C omitting the heating step. The solvent of the combined supernatants (700 µL) was 
then evaporated until dryness at 40 °C under a gentle stream of nitrogen gas. The 
residue was resuspended in 200 µL of water under vigorous vortexing and then analyzed 
by reversed phase-HPLC-MS/MS. Extractions were performed in triplicate with two 
independent bacterial cultures as biological duplicate. 
 Protein content was determined by dissolving the cell pellet of 1 mL aliquots of 
the bacterial cultures in 800 µL of 0.1 M NaOH by heating for 15 minutes at 95 °C and 
subsequently performing a protein determination with a BCA (bicinchoninic acid) assay 
(Thermo Scientific, Rockford, IL, USA). Measurements were repeated in triplicate and 
final c-di-GMP concentrations were expressed as pmol/mg of bacterial protein. 
 
4.3.5 Quantitation of c-di-GMP by HPLC-MS/MS 
The chromatographic separation was performed on a Series 200 HPLC system (Perkin 
Elmer Instruments, Norwalk, CT, USA) equipped with a binary pump system and a 
200 µL sample loop. A combination of Supelco Column Saver (2.0 µm filter, Supelco 
Analytical, Bellafonte, CA, USA), Security Guard Cartridge (C18, 4 x 2 mm) in an 
Analytical Guard Holder KJO-4282 (Phenomenex, Aschaffenburg, Germany) and an 
analytical NUCLEODUR C18 Pyramid RP column (50 x 3 mm, 3 µm particle size, 
Macherey-Nagel, Düren, Germany) temperature-controlled by a convenient HPLC column 
oven (Series 200 Peltier column oven, Perkin Elmer Instruments) at 30 °C was used. 
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 Eluent A consisted of 10 mM ammonium acetate and 0.1% (v/v) acetic acid in 
water and eluent B was methanol. The injection volume was 50 µL and the flow rate was 
0.4 mL/min throughout the chromatographic run. Eluent A (100%) was used from 0 to 
5 minutes followed by a linear gradient from 100% A to 70% A until 9 minutes. The 
internal standard cXMP and c-di-GMP were eluted during this gradient phase with 
retention times of 6.1 and 8.6 minutes, respectively. Re-equilibration of the column was 
achieved by constantly running 100% A from 9 to 13 minutes. 
 The analyte detection was performed on an API 3000 triple quadrupole mass 
spectrometer equipped with an electro spray ionization (ESI) source (Applied Biosystems 
Inc, Foster City, CA, USA) using selected reaction monitoring (SRM) analysis in positive 
ionization mode. The following SRM transitions using a dwell time of 40 ms were 
detected: cXMP: +347/153 (quantifier), +347/136 (qualifier); c-di-GMP: +691/152 
(quantifier), +691/135 and +691/248 (qualifier). The SRM transitions labeled as 
“quantifier” were used to quantify the compound of interest whereas “qualifier” SRM 
transitions were monitored as confirmatory signals. The quantifier SRM transitions were 
most intense and were therefore used for quantitation. The same quantifier (+691/152) 
and one of the two qualifier (+691/248) SRM transitions for c-di-GMP were also reported 
by Hickman and Harwood, 2008. The mass spectrometer parameters were as follows: IS 
voltage: 5500 V, temperature: 350 °C, nebulizer gas: 6 psi, curtain gas: 15 psi. MS/MS 
was performed using nitrogen as collision gas. The following collision energies were 
applied: 29 eV (+347/153), 59 eV (+347/136), 61 eV (+691/152), 123 eV (+691/135), 
39 eV (+691/248). 
 
 
4.4 Results 
4.4.1 HPLC-MS/MS Method Performance 
We have developed an HPLC-MS/MS method for the quantitation of c-di-GMP which was 
validated regarding various method performance parameters (see Table 4.1): limit of 
detection (LOD, signal-to-noise (S/N) ratio 3:1), lower limit of quantitation (LLOQ), 
squared correlation coefficient (R2), intra- and inter-day precision by means of relative 
standard deviation (RSD), accuracy, extraction recovery and 24 h stability of c-di-GMP. 
These performance characteristics were determined according to the Guidance for 
Industry, Bioanalytical Method Validation20. 
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Table 4.1 Method performance parameters determined by HPLC-MS/MS for three c-di-GMP 
standards. 
Retention time (min) 8.6   
LOD (ng/mL) 1.2   
LLOQ (ng/mL) 4.1   
Linearitya (R2) 0,9999   
 c-di-GMP standards (ng/mL) 
 10 50 500 
RSD intra-dayb (%) 10.9 7.8 2.7 
RSD inter-dayb (%) 11.2 6.4 5.9 
Accuracy (%) 85-109 89-109 96-101 
Recoveryc (%) 76.4 74.2 108.4 
Drug stabilityd (%) 73.7 74.8 91.5 
a c(c-di-GMP) = 4-1000 ng/mL 
b n = 5 
c nucleotide extraction recovery, n = 5 
d room temperature for 24 h, n = 5 
 
 The extraction and quantitation of c-di-GMP in bacteria is shown exemplarily for 
Escherichia coli cultivated in TB, and was analogously applied for other bacterial strains 
in various liquid culture media (data not shown). Hence, the validation was performed in 
water (except for extraction recovery experiments) in order to ascertain the performance 
parameters in a standard matrix. c-di-GMP possessed a retention time of 8.6 minutes in 
the established HPLC procedure. LOD and LLOQ were in the low nanogram/mL range 
(Table 4.1). Standard calibration curves for the detection of validation parameters were 
acquired ranging from 4 to 1,000 ng/mL with R2 values close to 1. The method was 
found to be linear up to 5,000 ng/mL. Intra- and inter-day precisions as well as 
accuracies for the different standard concentrations examined were within the required 
range (< 15%) according to the Guidance for Industry, Bioanalytical Method Validation20. 
Furthermore, acceptable recovery rates have been determined and the 24 h stability 
tests of c-di-GMP at room temperature showed slight degradation which was more 
pronounced at lower c-di-GMP concentrations. 
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Fig. 4.1 Detection of c-di-GMP in different matrices with the internal standard cXMP (200 ng/mL) by 
HPLC-tandem mass spectrometry displaying the SRM transition 691  152: Standard sample of 
c-di-GMP at the LLOQ (4.1 ng/mL) in water (a), c-di-GMP in a bacterial extract of Escherichia coli at 
an OD600 of 1.42 (b) and 0.5 (c(c-di-GMP) < LOD) (c). The peaks labeled with an asterisk represent 
interfering endogenous metabolites in the bacterial extract of Escherichia coli. The inserts represent 
enlargements of the low intensity peaks. 
 
 The HPLC-MS/MS method was applied to the detection and quantitation of 
c-di-GMP in bacterial extracts. Fig. 4.1 displays chromatographic runs with the internal 
standard cXMP and c-di-GMP both in water and in extraction matrix (bacterial extracts of 
Escherichia coli at different optical densities). The c-di-GMP peak in the bacterial extract 
(OD600 1.42) was clearly identified by its retention time and its distinct SRM transitions 
(see “Materials and Methods”). Additional endogenous metabolites having the same 
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quantifier SRM transition as c-di-GMP (+691/152) appeared at 5.6 and 8.9 minutes (see 
Fig. 4.1), the latter being base-line separated from the c-di-GMP peak (8.6 minutes). The 
unidentified metabolites and c-di-GMP also had one qualifier SRM transition in common 
(+691/135) whereas the second qualifier SRM transition (+691/248) was unique to 
c-di-GMP. The presented method can also be used for the detection and quantitation of 
cyclic 3’:5’-di-adenosine monophosphate (c-di-AMP) with a retention time of 9.3 min 
(data not shown). 
 
4.4.2 Di-Guanylate Cyclase Assay with PleD* 
Biochemical analysis of purified enzymes is a major tool in order to identify and 
characterize enzymatic activities. The family of di-guanylate cyclases comprises key 
enzymes of second messenger signaling in bacteria. DGCs require dimerization for their 
catalytic activity which is responsible for the condensation of two GTP molecules into 
c-di-GMP. For this study, we extracted and purified the 50 kDa DGC PleD* as a model 
enzyme which is a constitutively active mutant of the Caulobacter crescentus DGC PleD6. 
We applied the newly developed reversed phase HPLC-MS/MS method to monitor the 
turnover of GTP to c-di-GMP by PleD* in an in vitro assay (Fig. 4.2). Under the chosen 
conditions, c-di-GMP production was linear up to 7 µg/mL (10 µM). The hyperbolic shape 
of the kinetic is presumably due to allosteric product inhibition at higher c-di-GMP 
concentrations21 although ki values have not yet been determined. 
 
 
 
 
 
 
 
 
 
 
Fig 4.2 Turnover of GTP to c-di-GMP by the constitutively active di-guanylate cyclase PleD* (for assay 
conditions see “Materials and Methods”). The response curve shows monophasic saturation and is 
fitted sigmoidally (R2 = 0.996). Error bars are standard deviations of the mean. Calculations and fit 
were conducted with Origin 8. 
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4.4.3 c-di-GMP Concentration along Growth Curve of Escherichia coli 
Changes of c-di-GMP levels along the growth curve were determined for the Escherichia 
coli wildtype strain MG1655. The experiment was performed in duplicate with two 
independent bacterial cultures. c-di-GMP was extracted at an optical density (OD600) of 
0.5 followed by extractions in one-hour intervals for six more hours. Corresponding 
OD600 values were measured at the time of extraction. The course of c-di-GMP 
concentration (mean values of biological duplicates) is displayed in Fig. 4.3. The 
c-di-GMP level rised from levels below the limit of detection during exponential growth, 
to a maximum concentration of 2.1 pmol/mg of bacterial protein at entry into stationary 
phase (OD600 of 1.34) and decreased again in latter stages of stationary phase. These 
results suggest that c-di-GMP levels are controlled in a growth phase-dependent manner. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3 Change of c-di-GMP concentration along growth curve of Escherichia coli. 
(LOD = < 0.9 pmol/mg of bacterial protein). Bars represent c-di-GMP concentrations with standard 
deviations of the mean. Error bars were calculated using Excel. 
 
 
4.5 Discussion 
The bacterial second messenger c-di-GMP regulates the transition from a motile 
planctonic lifestyle to a sessile biofilm-forming state in a wide range of species and is 
responsible for the switch between virulence and persistence. For a detailed 
understanding of the regulatory mechanisms of the c-di-GMP signaling system, a reliable 
and sensitive c-di-GMP quantitation method for in vitro and in vivo experiments is 
essential. Our study presents the development and validation of a suitable reversed 
phase-HPLC-MS/MS method. 
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 The method as presented here possesses several advantages compared to 
existing HPLC or mass spectrometry based methods. For example, detection of c-di-GMP 
by UV absorption at 254 nm after HPLC separation requires complete peak separation 
and is, thus, not ideal to quantify c-di-GMP in cellular extracts containing high 
concentrations of related nucleotides such as GTP and ATP. As a consequence, HPLC-UV 
analysis is only suitable to determine c-di-GMP when DGCs are overexpressed22. 
 c-di-GMP levels in bacterial extracts have been measured by using MALDI-TOF 
mass spectrometry16. This method requires a separate chromatographic work-up for the 
isolation of c-di-GMP. Successively collected 1 mL elution fractions have to be separately 
processed and individually subjected to mass spectrometric analysis. Moreover, the 
varying quality of the sample spot, the uneven matrix crystallization and unequal 
spreading of matrix on the template are unsolved technical problems associated with 
MALDI-TOF technology. Hence, MALDI-TOF mass spectrometry is limited in terms of 
reliability and reproducibility. In contrast, the direct coupling of chromatographic 
separation to the tandem mass spectrometer via electrospray ionization (ESI) as 
described here facilitates the quantitation of c-di-GMP with high sensitivity which is 
comparable to the described MALDI-TOF method. 
 Some liquid chromatography tandem mass spectrometry methods for the 
detection of c-di-GMP have been reported before17,3,18. However, the published methods 
have several drawbacks. A validation supporting their reliability has not yet been 
performed. In some cases, the individual chromatographic runs are time-consuming (up 
to 45 minutes) which is disadvantageous when high sample throughput is required. 
Moreover, a reliable quantitation by mass spectrometry requires the inclusion of an 
adequate internal standard (IS). We use cyclic 3’:5’-xanthosine monophosphate (cXMP) 
which (a) is structurally related to the analyte due to its nucleotide character and (b) is 
absent from bacteria and hence does not interfere with the extraction of endogenous 
nucleotides. 
 Tandem mass spectrometers are highly selective due to the detection of specific 
molecular fragments. Depending on the instrumentation and the used ion source, a so-
called “in-source fragmentation” can occur. Thereby, the analyte molecule decomposes 
into smaller fragments during the ionization process directly at the ion source even 
before reaching the collision cell or any of the mass discriminating fields of the mass 
spectrometer. c-di-GMP can undergo decomposition to cyclic 3’:5’-guanosine 
monophosphate (cGMP). This has to be considered and corrected for if the extent of in-
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source fragmentation is significantly high. However, HPLC-coupled ESI-MS/MS analysis 
still displays higher specificity compared to single-MS or non-MS methods. 
 The validation performance parameters (see Table 4.1) of the presented reversed 
phase-HPLC-MS/MS method are within the required ranges (Guidance for Industry, 
Bioanalytical Method Validation20), which renders the method useful for the detection of 
c-di-GMP in biological assays. The extraction recovery rates (see Table 4.1) for low 
concentration standards (10 and 50 ng/mL) are smaller than for the high concentration 
standard (500 ng/mL). Losses during the extraction process are more pronounced in 
samples spiked with low, compared to high, amounts of c-di-GMP. This accounts for the 
different recovery rates of the three c-di-GMP standards. Furthermore, the 24 h stability 
of c-di-GMP at room temperature (see Table 4.1) is superior at increased c-di-GMP 
concentrations. This finding can be possibly attributed to the formation of dimers or even 
tetramers of c-di-GMP as proposed in an earlier study23. Supposedly, c-di-GMP is 
stabilized in these aggregates at higher concentrations. 
 The application of both detection and quantitation methods to biological samples 
can suffer from interfering substances in the biological matrix. In a previous study, an 
unknown compound was identified by HPLC-MS/MS analysis in extracts of Vibrio cholerae 
with a retention time and molecular mass close to c-di-GMP18. These findings illustrate 
that chromatographic conditions have to be highly optimized for the identification and 
separation of analyte peaks, not only in standard samples but particularly in biological 
matrices. In bacterial extracts of Escherichia coli we found two matrix peaks at 5.6 and 
8.9 minutes (see Fig. 4.1), the latter being base-line separated from the c-di-GMP peak 
at 8.6 minutes. Only two of the three SRM transitions for c-di-GMP can be found for the 
peak at 8.9 minutes. Moreover, both unknown peaks appear with the same intensity in 
both samples with and without quantifiable amounts of c-di-GMP as indicated in Fig. 4.1. 
In extracts of different bacterial species, a similar peak was observed close to the 
retention time of c-di-GMP (data not shown). In the in vitro assay with the constitutively 
active DGC PleD* (see Fig. 4.2) the additional peak close to c-di-GMP did not appear. 
Hence, the unknown peaks in the bacterial extracts of Escherichia coli seem to be 
interfering endogenous bacterial metabolites which can be clearly discriminated from 
c-di-GMP with our method and do not interfere with its quantitation. 
 Apart from the direct determination of c-di-GMP levels in bacterial cells, the 
identification and characterization of protein domains participating in c-di-GMP 
metabolism is of basic interest. The activities of GGDEF and EAL domains have been 
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determined by in vitro biochemical analyses. We applied our HPLC-MS/MS method for 
the establishment of an in vitro DGC assay with the constitutively active DGC PleD*. The 
method can serve as a simple, reliable and very sensitive approach for the analysis of 
newly discovered c-di-GMP producing enzymes and thus contributes to the elucidation of 
their role in the c-di-GMP regulatory system. 
 The virulence and persistence of many bacterial pathogens is strongly dependent 
on their lifestyle. The expression of virulence factors is favored in the planctonic state, 
whereas chronic infections are often characterized by the formation of robust biofilms 
which persist despite attacks by the immune system and antimicrobial treatment. The 
second messenger c-di-GMP plays a key role in the adaptation process of bacteria to 
their environment. We measured the change of c-di-GMP levels in liquid cultures of 
Escherichia coli along the growth curve and observed clear fluctuations dependent on 
the optical density. An increase in c-di-GMP concentrations during the exponential 
growth phase with a maximum at an OD600 of 1.34 at the entry into the stationary phase 
is followed by a smooth decrease in the stationary phase. This implies that the 
Escherichia coli c-di-GMP signaling network clearly responds to environmental conditions 
via up- or down-regulation of c-di-GMP metabolism. The variation of in vivo c-di-GMP 
levels of bacterial communities during colonization and biofilm formation on suitable 
templates remains to be determined. A modification of the presented extraction 
procedure for bacterial liquid cultures can offer the possibility to extract c-di-GMP from 
biofilms grown on solid templates as described in another study for cultures grown on 
filter templates19. The study of c-di-GMP levels in biofilms could foster the development 
of strategies which help to avoid the formation of persistent bacterial communities and 
the resulting antibiotic resistance. The determination of overall c-di-GMP levels in intact 
bacteria is an important step towards the understanding of c-di-GMP metabolism 
concerning the cooperative effects of c-di-GMP metabolizing enzymes. However, there 
are hints that enzymes involved in c-di-GMP metabolism are targeted to specific sites in 
the bacterial cell6 possibly leading to only locally elevated c-di-GMP levels. Hence, the 
identification and quantitation of local c-di-GMP pools is the great challenge for the 
future. 
 In conclusion, our study shows that the novel reversed phase-HPLC-MS/MS 
method combined with an efficient nucleotide extraction procedure serves as a robust, 
specific, and sensitive tool for both the in vitro biochemical analysis of c-di-GMP-
generating or -degrading enzymes and the determination of in vivo c-di-GMP 
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concentrations. Hence, our method can contribute to better understand the complex 
c-di-GMP signaling network in bacteria. The described method has been successfully 
applied to two studies aimed at the identification and characterization of novel c-di-GMP 
regulatory systems24,25. 
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5. Interaction of the Di-Guanylate Cyclase YdeH of 
Escherichia coli with 2’,(3’)-Substituted Purine and 
Pyrimidine Nucleotides 
5.1 Abstract 
Di-guanylate cyclases (DGCs) synthesize the bacterial intracellular second messenger 
cyclic 3’:5’-di-guanosine monophosphate (c-di-GMP) which is degraded by specific 
phosphodiesterases (PDEs). c-di-GMP levels control the transition of bacteria from a 
motile to a biofilm forming lifestyle. These bacterial communities are highly resistant to 
antibiotic treatment and represent the predominant lifestyle in most chronic infections. 
Hence, DGCs serve as starting-point for the development of novel therapeutics 
interfering with the second messenger signaling network in bacteria. In previous studies 
we showed that 2’(3’)-O-(N-methylanthraniloyl) (MANT)- and 2’,3’-O-(2,4,6-
trinitrophenyl) (TNP)-substituted nucleotides are potent adenylyl and guanylyl cyclase 
inhibitors. The catalytic domain of DGCs is homologuous to the mammalian adenylyl 
cyclase catalytic domain. Therefore, we investigated the interaction of various MANT 
purine and pyrimidine nucleotides with the model DGC YdeH from Escherichia coli. We 
observed strong fluorescence resonance energy transfer (FRET) between tryptophan and 
tyrosine residues of YdeH and the MANT-group of MANT-NTPs (MANT-ATP, -CTP, -GTP, -
ITP, -UTP, and -XTP) and an enhanced direct MANT fluorescence upon interaction with 
YdeH. We assessed the affinity of MANT-NTPs to YdeH by performing competition assays 
with NTPs. We conducted an amino acid alignment of YdeH with the earlier crystallized 
Caulobacter crescentus DGC PleD and found high similarities in the nucleotide binding 
site of PleD. In vitro mass-spectrometric activity assays with YdeH resulted in the 
identification of new MANT/TNP nucleotide-based inhibitors of DGC activity. Collectively, 
the analysis of interactions between MANT/TNP nucleotides and YdeH provided a new 
basis for the identification and development of DGC inhibitors and allows insights into 
nucleotide-protein interactions. 
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5.2 Introduction 
Bacteria universally form communities by attachment and aggregation on a surface 
which may take many forms such as inert solid materials, living tissue or boundary 
surfaces in aquatic systems1. These biofilms are characterized by the formation of an 
exopolysaccharide matrix in which the microorganisms are encased2. One or more 
different bacterial species can accumulate in one single biofilm. For example dental 
biofilms are estimated to contain more than 500 bacterial species3. Biofilm-grown cells 
are highly persistent and, in contrast to planctonic cells, display increased resistance to 
antimicrobial treatment and host defense. Most chronic bacterial infections result from 
the formation of stable biofilms. In case of cystic fibrosis, the airways of patients are 
infected by Pseudomonas aeruginosa4. Biofilm formation on diagnostic or surgical 
medical devices also poses a serious problem for public health5. The mechanisms of 
antibiotic resistance are only partially understood (for review see Refs. 6 and 7). Hence, 
the development of effective antibiotics is stagnant. Only few chemical compounds 
capable of affecting biofilm formation have been identified8,9. 
 The transition from a motile, planctonic lifestyle to a sessile, cooperative lifestyle 
is regulated by the bacterial second messenger cyclic 3’:5’-di-guanosine monophosphate 
(c-di-GMP) (for review see Ref. 10). In general, elevated levels of c-di-GMP account for 
increased biofilm formation. c-di-GMP is synthesized by di-guanylate cyclases (DGCs) via 
the condensation of two GTP molecules and degraded by specific phosphodiesterases 
(PDEs) to GMP via the linear intermediate pGpG. These two highly abundant protein 
families in bacteria contain the conserved GGDEF and EAL domains, respectively11,12. In 
most cases, a single bacterial genome encodes many different members of these protein 
families13. Hence, c-di-GMP-metabolizing enzymes, especially DGCs as key enzymes of 
second messenger signaling in bacteria, constitute a pharmacological target for the 
developement of possible inhibitors capable of affecting c-di-GMP biosynthesis and 
biofilm formation. 
 In previous studies, we identified various 2’(3’)-O-(N-methylanthraniloyl) (MANT)-
substituted nucleotides as potent inhibitors of the bacterial adenylyl cyclase (AC) toxin 
edema factor (EF) and of mammalian membrane ACs (mACs) by both enzymatic and 
fluorescence spectroscopy methods14,15. Moreover, 2’,3’-O-(2,4,6-trinitrophenyl) (TNP)-
substituted nucleotides are potent inhibitors of various AC isoforms and soluble guanylyl 
cyclase (GC)16. Sequence similarity between the GGDEF domain and mAC catalytic 
domain has been detected17. From this homology, it was deduced that the fold of the 
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GGDEF domain is similar to the mAC catalytic domain. This finding prompted us to 
investigate the interaction of different MANT-substituted nucleotides with a model DGC. 
For this purpose, we used the DGC YdeH from Escherichia coli. The YdeH gene has been 
identified as target for the carbon storage regulator CsrA, an RNA-binding protein which, 
amongst others, controls biofilm formation18. Later, it was shown that YdeH possesses in 
vitro DGC activity19. However, in a previous study it was shown that despite the similar 
fold of the DGC domain and the mAC domain, the nucleotide-binding mode in the DGC 
PleD from Caulobacter crescentus is substantially different20. 
 In this study, we investigated the interaction between MANT-/TNP-substituted 
nucleotides and the DGC YdeH by fluorimetric and mass-spectrometric means. In a first 
approach, we evaluated the affinity of MANT nucleotides to YdeH by performing 
fluorescence competition assays with unsubstituted nucleotides and assessed structural 
aspects of nucleotide binding by YdeH via amino acid alignment with the DGC PleD. The 
DGC activity of YdeH was determined in vitro using sensitive HPLC-coupled tandem mass 
spectrometry. The in vitro analysis of a series of MANT- or TNP-substituted nucleotides 
for their potential inhibitory effect on DGC activity of YdeH resulted in the identification 
of three GTP-based YdeH inhibitors. 
 
 
5.3 Materials and Methods 
5.3.1 Chemicals 
Solvents used in HPLC analysis were water, methanol, and acetonitrile (HPLC-gradient 
grade, J. T. Baker, Deventer, The Netherlands). Isopropyl β-D-1-thiogalactopyranoside 
(IPTG), ammonium acetate, bovine serum albumin (BSA), L-glutamic acid, L-arginine, 
adenosine 5’-triphosphate (ATP), guanosine 5’-triphosphate (GTP), inosine 5’-
triphosphate (ITP), uridine 5’-triphosphate (UTP), and guanosine-13C10,15N5 5’-
triphosphate sodium salt were purchased from Sigma Aldrich (Steinheim, Germany). 
Cytidine 5’-triphosphate (CTP), xanthosine 5’-triphosphate (XTP), MANT-ATP, MANT-
GTP, MANT-XTP, MANT-GTPγS, and TNP-GTP were from Jena Bioscience (Jena, 
Germany). Sodium chloride, sodium hydroxide, tris(hydroxymethyl)-aminomethane, 
magnesium chloride hexahydrate, and sodium dihydrogen phosphate were obtained 
from Merck (Darmstadt, Germany), acetic acid was from Riedel-de Haen (Hannover-
Seelze, Germany), and imidazole from Carl Roth (Karlsruhe, Germany). Complete, EDTA-
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free protease inhibitor cocktail tablets were purchased from Roche Diagnostics 
(Mannheim, Germany). Cyclic 3’:5’-di-guanosine monophosphate (c-di-GMP) was kindly 
provided by BioLog (Bremen, Germany). MANT-CTP, MANT-ITP, and MANT-UTP were 
synthesized as described14. 
 
5.3.2 Expression and Purification of YdeH 
C-terminally His6-tagged YdeH was expressed from a pET28 vector in the Escherichia coli 
Rosetta strain kindly provided by Drs. U. Jenal and A. Böhm, Molecular Microbiology 
Division, Biozentrum, University of Basel, Switzerland. Cells were grown in LB medium 
supplemented with kanamycin (50 µg/mL) and chloramphenicol (30 µg/mL) and 
expression of YdeH was induced by the addition of isopropyl 1-thio-β-D-
galactopyranoside (1 mM) for 3 hours at 30 °C. Cells were harvested by centrifugation, 
resuspended in lysis buffer (50 mM NaH2PO4 pH 7.5, 200 mM NaCl, 10 mM imidazole, 
50 mM L-glutamic acid, 50 mM L-arginine) containing EDTA-free protease inhibitor 
cocktail (1 tablet/50 mL buffer) and lysed by ultrasonic treatment on ice using seven 
30 second burst periods at 250 W with 30 second cooling periods in between. The lysate 
was cleared by centrifugation (20.000 x g) and the supernatant fluid was filtered 
(0.22 µm). YdeH was purified by Ni-NTA affinity chromatography using a 5 mL 
HisTrap FF column (GE Healthcare, Munich, Germany). After washing the column with 
lysis buffer (without protease inhibitors), YdeH was eluted with a linear gradient of 
imidazole from 10 to 500 mM. Desalting and buffer exchange of pooled fractions were 
performed on a 5 mL HiTrap Desalting column (GE Healthcare). Final protein 
concentration was determined with a Bradford assay (Carl Roth, Karlsruhe, Germany). 
 
5.3.3 Fluorescence Experiments for Monitoring MANT-Nucleotide Binding to 
YdeH 
Fluorescence experiments were performed using a quartz UV ultra-microcuvette from 
Hellma (Müllheim, Germany, type 105.251-QS) in a Varian Cary Eclipse fluorescence 
spectrometer (Varian, Palo Alto, CA, USA). Reaction mixtures contained 5 mM MnCl2 and 
50 mM NaCl in 50 mM TRIS-HCl pH 8.0, followed by sequential addition of MANT 
nucleotides (1 µM final concentration) and YdeH (5 µM final concentration) in a total 
assay volume of 100 µL. Steady-state fluorescence emission spectra of MANT 
nucleotides were recorded at low-speed in the scan mode. In fluorescence resonance 
energy transfer (FRET) experiments, the excitation wavelength was λex = 280 nm with 
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λem = 305-540 nm, whereas in direct fluorescence experiments, the MANT group was 
excited at λex = 350 nm, and the emission was recorded at λem = 380-540 nm. In kinetic 
competition experiments, MANT nucleotides where displaced from YdeH by sequential 
addition of increasing concentrations of nucleotides to the assay mixture. Direct 
fluorescence emission of MANT nucleotides was recorded at λem = 440 nm after 
excitation at λex = 350 nm. 
 
5.3.4 YdeH in vitro Activity Assay 
In DGC activity assays, 10 nM YdeH was used. MgGTP concentrations were varied 
between 100 nM and 1 mM. The standard reaction mixture contained 50 mM TRIS-HCl 
pH 8.0, 5 mM MgCl2, 0.1% (m/v) BSA in a total assay volume of 50 µL. The temperature 
was set to 30 °C. The reaction was initiated by the addition of YdeH and was stopped 
after 30 minutes by heat-inactivation at 95 °C for 5 minutes. The resulting suspension 
was centrifuged (20.000 x g) in order to remove denatured protein. c-di-GMP 
concentration was determined in the supernatant by high performance liquid 
chromatography-coupled tandem mass spectrometry (HPLC-MS/MS) as described21 
except for the use of the enzymatically synthesized internal standard 13C20,15N10 cyclic 
3’:5’-di-guanosine monophosphate (13C20,15N10-c-di-GMP) (synthesis protocol see below) 
instead of cyclic 3’:5’-xanthosine monophosphate (cXMP). 13C20,15N10-c-di-GMP was 
present in a final concentration of 200 ng/mL and was detected using selected reaction 
monitoring (SRM) analysis in positive ionization mode with an SRM transition of 
+721/162 and a collision energy of 61 eV. 
 Assay mixtures for the inhibition experiment of YdeH with MANT-GTP contained 
MANT-GTP at final concentrations of 100 nM, 300 nM, 1 µM, 3 µM, and 10 µM. Inhibition 
experiments with MANT-GTPγS and TNP-GTP additionally contained the inhibitors at final 
concentrations of 10 nM and 30 nM. In screening experiments for potential DGC 
inhibitors, MANT- or TNP-substituted nucleotides were present at a concentration of 
10 µM. Inhibition experiments were performed under conditions as described above with 
5 µM Mg/GTP as substrate and an incubation time of 15 minutes. All assays were 
performed in triplicate. 
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5.3.5 Enzymatic Synthesis of 13C20,
15N10 Cyclic Di-Guanosine Monophosphate 
For the synthesis of 13C20,15N10 cyclic 3’:5’-di-guanosine monophosphate (13C20,15N10-
c-di-GMP) 2 µM YdeH was incubated with 500 µM guanosine-13C10,15N5 5’-triphosphate in 
50 mM TRIS-HCl pH 8.0, 5 mM MgCl2, and 0.1% (m/v) BSA for 18 hours at 30 °C. From 
an identical experiment using unlabeled GTP substrate it can be deduced that substrate 
turnover is complete under these conditions. The reaction was stopped by heating to 
95 °C for 15 minutes and the suspension was clarified by centrifugation (20.000 x g). 
The concentration of 13C20,15N10-c-di-GMP in the supernatant fluid was determined by 
measuring the absorption at 254 nm (ε254 = 23.700 M-1 cm-1). Further purification steps 
were not necessary for the use of 13C20,15N10-c-di-GMP as internal standard and were 
therefore omitted. 
 
 
5.4 Results 
5.4.1 Interaction of MANT Nucleotides with YdeH in Steady State 
Fluorescence Experiments 
Tryptophan and tyrosine residues represent intrinsic fluorophores in proteins and can be 
excited at λex = 280 nm resulting in endogenous fluorescence with a maximum at 
λem = 350 nm as indicated for YdeH in Figs. 5.1a-f. MANT nucleotides exhibited only 
minimal endogenous fluorescence after excitation at λex = 280 nm. After addition of 
YdeH to all MANT nucleotides investigated, distinct new fluorescence signals appeared in 
presence of Mn2+ with a maximum ranging from 425 to 435 nm (Figs. 5.1a-f). These 
peaks are ascribed to fluorescence resonance energy transfer (FRET) from tryptophan 
and tyrosine residues to the MANT group. The extent of FRET was comparable for all 
examined MANT nucleotides. In presence of Mg2+, FRET signals were smaller or even 
disappeared (data not shown). Lower FRET intensities with MANT nucleotides using 
Mg2+- compared to Mn2+-containing buffers have also been detected earlier in 
experiments with mACs22. Although Mg2+ is the physiologically relevant cation, all 
fluorescence studies were conducted with Mn2+. The reversibility of MANT nucleotide 
binding to YdeH was examined by the addition of 10 µM GTP. As a consequence, the 
FRET signals considerably decreased. In case of MANT-GTP, only a very small effect was 
observed. With the applied GTP concentration, the FRET signals did not disappear 
completely as indicated by the remaining shoulders between 400 and 500 nm. 
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Fig. 5.1 Analysis of MANT-NTP (NTP = ATP, CTP, GTP, ITP, UTP, XTP) interaction with YdeH by 
performing both FRET and direct fluorescence studies as described under “Materials and Methods”. 
The following components were added consecutively: MANT nucleotide, 1 µM (black); YdeH, 5 µM 
(blue); GTP, 10 µM (red). YdeH alone, 5 µM, is represented in grey. Representative FRET experiments 
(λex = 280 nm) and direct fluorescence experiments (λex = 350 nm) are shown in panels a-f and g-l, 
respectively. 
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 We additionally studied the changes of direct MANT nucleotide fluorescence after 
interaction with YdeH at an excitation wavelength of λex = 350 nm. MANT nucleotides 
exhibited strong endogenous fluorescence peaking at λem = 450 nm (Figs. 5.1g-l). In 
presence of YdeH, the fluorescence intensity was enhanced by a factor of 2 to 2.5 
accompanied by a shift of the emission maximum to shorter wavelengths (blue-shift) by 
about 10-20 nm, depending on the MANT nucleotide studied. This blue-shift has been 
observed in binding studies of MANT nucleotides to bacterial and mammalian ACs16,22 
and is ascribed to the movement of the MANT group into a more hydrophobic 
environment23. The addition of 10 µM GTP reduced the fluorescence of the MANT 
nucleotides to almost the endogenous fluorescence intensities in absence of YdeH, 
except for MANT-GTP whose fluorescence was only marginally decreased. This goes 
along with the before-mentioned small reduction of FRET signal in case of MANT-GTP. 
 
5.4.2 Competition Studies Between MANT Nucleotides and NTPs for Binding 
to YdeH 
We examined the reversibility of MANT nucleotide fluorescence enhancement after 
interaction with YdeH in competition assays with different NTPs (ATP, CTP, GTP, ITP, 
and UTP) by monitoring changes in direct MANT fluorescence. Fig. 5.2 exemplarily shows 
the kinetics of MANT-ATP (Figs. 5.2a-c) and MANT-GTP (Figs. 5.2d-e) fluorescence at 
λem = 440 nm after excitation at λex = 350 nm. In presence of YdeH, a pronounced 
fluorescence increase for both MANT nucleotides was observed. The response time of 
MANT nucleotide florescence was on a time scale of a few seconds at the most. The 
sequential addition of increasing concentrations (0.1 µM to 50 µM) of GTP or ATP 
resulted in differently pronounced fluorescence decreases. 
 After addition of GTP and ATP, the fluorescence intensity of MANT-ATP was 
reduced to the original level in absence of YdeH (Figs. 5.2a and b). Very similar results 
were obtained after addition of CTP, ITP, and UTP (data not shown). The endogenous 
MANT-ATP fluorescence remained constant over time in control experiments (with all 
NTPs examined) where buffer was added instead of YdeH at time point (1) (Fig. 5.2c: 
addition of ATP). 
 The emission intensity of MANT-GTP was decreased to a lesser extent even in 
presence of high concentrations of NTPs (50 µM). The five NTPs examined showed 
slightly different potencies of reducing YdeH-induced MANT-GTP fluorescence: 
GTP > ITP > ATP/UTP > CTP. Figs. 5.2d-f exemplarily show changes in MANT-GTP 
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fluorescence after addition of GTP and ATP (data for CTP, ITP, and UTP not shown) and 
a representative control experiment with ATP where YdeH was replaced by buffer. 
Controls were performed for all NTPs examined. No changes in MANT-GTP fluorescence 
were detected under these conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2 Kinetic analysis of the competition of MANT nucleotides and NTPs for binding to YdeH in 
fluorescence experiments. The following components were added consecutively to cuvettes containing 
MANT nucleotide (1 µM; a-c: MANT-ATP, d-f: MANT-GTP): (1) YdeH (5 µM; panels c and f: buffer 
instead of YdeH as control); NTPs: (2) 0.1 µM, (3) 0.5 µM, (4) 1 µM, (5) 2.5 µM, (6) 5 µM, (7) 10 µM, 
(8) 50 µM; panels a and d: GTP, panels b, c, e, f: ATP. Excitation wavelength was set to 
λex = 350 nm and emission of MANT nucleotides was detected at λem = 440 nm over time. 
 
5.4.3 YdeH in vitro Activity Assay 
Assays monitoring c-di-GMP production by YdeH were performed using reversed-phase 
high performance liquid chromatography-coupled tandem mass spectrometry (HPLC-
MS/MS)21. The reported method was modified in terms of using a newly synthesized 
internal standard (IS), 13C20,15N10 cyclic 3’:5’-di-guanosine monophosphate (13C20,15N10-
c-di-GMP), instead of cyclic 3’:5’-xanthosine monophosphate (cXMP). 13C20,15N10-
c-di-GMP was enzymatically produced using YdeH. Although DGCs all exhibit strong 
product inhibition, YdeH has a comparably high residual DGC activity19 which is sufficient 
for the production of 13C20,15N10-c-di-GMP from guanosine-13C10,15N5 5’-triphosphate. 
a
b
c
d
e
f 
0 2 4 6 8 10 12 14 16 18
20
40
60
80
100
876542 31
t (min)
F
 (
a
.u
.)
MANT-ATP + GTP
0 2 4 6 8 10 12 14 16 18
20
40
60
80
MANT-GTP + GTP
3 4 5 6 7 821
t (min)
F
 (
a
.u
.)
0 2 4 6 8 10 12 14 16 18
20
40
60
80
100
MANT-ATP + ATP
8765432
F
 (
a
.u
.)
t (min)
1
0 2 4 6 8 10 12 14 16 18
20
40
60
80
100
87654321
MANT-GTP + ATP
t (min)
F
 (
a
.u
.)
0 2 4 6 8 10 12 14 16 18
20
40
60
80
100
1 2 3 4 5 6 87
t (min)
F
 (
a
.u
.)
0 2 4 6 8 10 12 14 16 18
20
40
60
80
100
87654321
F
 (
a
.u
.)
5. Interaction of the DGC YdeH with Substituted Nucleotides 77 
Fig. 5.3 shows a representative chromatographic run with 13C20,15N10-c-di-GMP and 
unlabeled c-di-GMP. The retention time of 13C20,15N10-c-di-GMP was identical in 
comparison with unlabeled c-di-GMP (8.6 minutes). In contrast, the formerly used IS 
cXMP eluted earlier than unlabeled c-di-GMP at 6.1 minutes. Due to the structural 
identity and equal chromatographic behavior compared to unlabeled c-di-GMP, 
13C20,15N10-c-di-GMP was used as IS for all mass spectrometric assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3 Detection of 13C20,
15N10-c-di-GMP (a) and unlabeled c-di-GMP (b) by HPLC-coupled tandem 
mass spectrometry (HPLC-MS/MS) at concentrations of 200 ng/mL and 128 ng/mL, respectively. 
Panels a and b show representative chromatograms of cyclic di-nucleotides dissolved in water with an 
identical retention time of 8.6 min. Boxes indicate the detected SRM transition. The fragmentation 
pattern of the respective cyclic di-nucleotides is indicated in the corresponding structures. Atoms with 
an asterisk are isotope-labeled: 13C (green), 15N (blue). 
 
 The rate of c-di-GMP production by YdeH was determined dependent on substrate 
concentration as indicated in Fig. 5.4. YdeH possessed exceptional enzyme kinetics. DGC 
activity was characterized by a steep increase at low substrate concentrations followed 
by a decreasing rate of c-di-GMP formation which then leveled off and remained 
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constant. Under the applied assay conditions, substrate turnover was higher than 10% 
for GTP concentrations up to 10 µM. Hence, it is likely for DGC activity to be subject to 
substrate depletion. Moreover, declining DGC activity determined for GTP concentrations 
higher than 10 µM is probably ascribed to product inhibition, resulting in a residual rate 
of c-di-GMP formation of about 0.75 min-1. 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4 Rate of c-di-GMP formation by YdeH as a function of substrate concentration using HPLC-
coupled tandem mass spectrometry (HPLC-MS/MS). YdeH was present at 10 nM. For assay conditions 
see “Materials and Methods”. Due to the unusual enzyme kinetics, data were not analyzed by non-
linear regression to calculate Km and Vmax values. Error bars are standard deviations of the mean. 
 
 The above-described fluorescence assays indicate that MANT-GTP seems to 
possess a relatively high affinity to YdeH compared to other MANT nucleotides. 
Therefore, we investigated the effect of MANT-GTP on the DGC activity of YdeH in detail 
(Fig. 5.5). The activity of YdeH was considerably reduced with increasing concentrations 
of MANT-GTP. Under the applied assay conditions (see “Materials and Methods”) an IC50 
of 0.5 µM was determined. We additionally performed inhibition assays with a set of 
MANT- and TNP-nucleotides which were applied at a concentration of 10 µM: MANT-ATP, 
-CTP, -ITP, -UTP, -XTP, -GTPγS, and TNP-GTP. The activity of YdeH was reduced to a 
level near the limit of detection only in presence of substituted GTP (MANT-GTPγS and 
TNP-GTP) whereas no change in DGC activity was observed for all other MANT-
substituted nucleotides. MANT-GTPγS and TNP-GTP had IC50 values of 0.2 µM and 
0.1 µM, respectively (see Fig. 5.5). 
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Fig. 5.5 Inhibition experiments of YdeH with MANT-GTP (squares), MANT-GTPγS (triangles), and 
TNP-GTP (circles) using HPLC-coupled tandem mass spectrometry. DGC activity was normalized with 
respect to the initial activity in absence of inhibitor. YdeH was present at 10 nM. For assay conditions 
see “Materials and Methods”. Error bars are standard deviations of the mean. 
 
 
5.5 Discussion 
Microorganisms preponderantly exist in biofilm forming communities which account for 
the high persistence in chronic infections and may cause severe problems due to the 
adherence to implanted medical devices5. The development of efficient therapeutic 
strategies against the formation of biofilms is difficult24. In this study, we assessed the 
inhibitory potential of MANT and TNP nucleotides on the model DGC YdeH as a basis for 
intervening in c-di-GMP metabolism of biofilm forming bacteria. 
 Our study demonstrates that MANT nucleotides (MANT-ATP, -CTP, -GTP, -ITP, -
UTP, and -XTP) undergo distinct fluorescent changes in both FRET and direct 
fluorescence experiments after interaction with YdeH (Fig. 5.1). All fluorescence 
experiments were performed with an excess of YdeH compared to the fluorescent ligand 
in order to obtain quantitative ligand binding and sufficient fluorescence signals. Notably, 
an increase in fluorescence was detected for all MANT nucleotides, not only for the 
MANT-substituted DGC substrate GTP. Both, the reduced FRET signals and decreased 
intrinsic MANT fluorescence after addition of GTP to the YdeH-MANT nucleotide 
complexes point to the displacement of MANT nucleotides from YdeH and binding of the 
original substrate GTP. However, Figs. 5.1c and i indicate that displacement of MANT-
GTP is clearly less pronounced compared to all other MANT nucleotides. This points at a 
high affinity of the GTP-group to YdeH. Competition experiments of MANT-ATP and 
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MANT-GTP with NTPs (ATP, CTP, GTP, ITP, and UTP) as exemplarily shown in Fig. 5.2 
support this finding: The direct fluorescence of MANT-ATP bound to YdeH is strongly 
reduced after successive addition of increasing concentrations of all NTPs examined, 
whereas in contrast, MANT-GTP fluorescence is decreased to a lesser extent in the same 
experiment. GTP is the most potent nucleotide in the MANT-GTP competition kinetics 
which can be ascribed to its function as natural substrate of DGCs. However, given the 
detected interaction between YdeH and MANT-NTPs other than MANT-GTP, one can 
speculate that YdeH optionally accepts other nucleoside 5’-triphosphates as substrate. In 
an in vitro assay with the highly active enzyme WspR the synthesis of c-di-dGMP and 
c-di-IMP from dGTP and ITP, respectively, was proposed, indicating a rather low 
substrate specificity of DGCs25. These data are in accordance with our findings. 
 The obvious binding capability of MANT-NTPs by YdeH offers the possibility of 
developing DGC inhibitors. Therefore, the mechanisms of inhibitor binding have to be 
elucidated in detail. The inhibitory characteristics of MANT-ATP and MANT-GTP and the 
underlying molecular binding mechanisms have been studied intensively for mammalian 
membrane ACs (mACs)15,22. From these studies we know that an increase in MANT 
fluorescence and a blue-shift of the emission maximum goes along with the interaction 
of the MANT fluorophore with nonpolar amino acid residues in a hydrophobic binding 
pocket. The homology between mAC and DGC catalytic domain may mislead to the 
assumption that the nucleotide binding mode was the same which, in contrast, is 
substantially different as shown for the crystal structure of the DGC PleD from 
Caulobacter crescentus solved in complex with the product c-di-GMP20. The authors 
proposed that the positions of the guanine, ribose and α-phosphoryl moieties in case of 
GTP binding are the same as in the complex structure with c-di-GMP. 
 In order to evaluate the nucleotide binding mode of YdeH we performed an 
amino acid alignment of PleD with YdeH (Fig. 5.6). Residues involved in GTP binding and 
the catalytic mechanism of c-di-GMP synthesis are conserved among the two DGCs. 
Hence, it is likely that the nucleotide binding mode of YdeH is comparable to PleD. We 
suggest that the MANT group of MANT-NTPs is transferred into a so far unspecified 
hydrophobic binding pocket as can be deduced from the fluorescence experiments. The 
exact binding mechanism of MANT nucleotides by YdeH remains to be elucidated 
experimentally. 
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  PleD   292 DQLTGLHNRRYMTGQLDSLVKRATLGGDPVSALLIDIDFFKK 333 
  YdeH   132 DVLTGLPGRRVLDESFDHQLRNAEPLN--LYLMLLDIDRFKL 171 
 
  PleD   334 INDTFGHDIGDEVLREFALRLASNVRAIDLPCRYGGEEFVVI 375 
  YdeH   172 VNDTYGHLIGDVVLRTLATYLASWTRDYETVYRYGGEEFIII 213 
 
Fig. 5.6 Amino acid alignment of the DGCs PleD from Caulobacter crescentus and YdeH from 
Escherichia coli. Residues necessary for GTP binding and catalytic activity in PleD (according to 
Ref. 20) are shaded gray and represent conserved amino acids also found in YdeH. 
 
 The enzymology of DGCs representing putative inhibitor targets needs to be 
elucidated in detail in order to develop new antimicrobial therapeutics. The conversion of 
GTP to c-di-GMP by YdeH dependent on substrate concentration was monitored with a 
modified HPLC-MS/MS method. The enzymatically synthesized internal standard (IS) 
13C20,15N10-c-di-GMP serves as ideal IS due to its identical molecular structure and 
retention time and further improves the described method. Hence, a reliable quantitation 
of c-di-GMP synthesis and DGC activity is possible. So far, the catalytic activity of YdeH 
has only been rudimentarily investigated19 with the objective of identifying YdeH as DGC. 
In the respective activity assay, YdeH was present at a very high concentration of 2 µM. 
We performed assays with 10 nM YdeH (Fig. 5.4) and observed exceptional enzyme 
kinetics. The course of the kinetics at low substrate concentrations (≤ 10 µM GTP) is 
hard to evaluate since it is likely for DGC activity to be affected by substrate depletion 
(GTP conversion > 10%). The following decline in DGC activity for substrate 
concentrations higher than 10 µM is probably due to product inhibition19, a general 
feature known for DGCs. However, YdeH has a relatively high residual DGC activity 
which is the reason for its application in the mass-spectrometric activity assay. In order 
to find out whether YdeH follows a Michaelis-Menten kinetic we tried to shorten the 
reaction time of the assay in order to avoid too high substrate conversions also for low 
substrate concentrations. Unfortunately, incubation times of only a few seconds would 
have had to be chosen which is experimentally difficult to accomplish. In addition, mass-
spectrometric signals would have been too small for accurate assessment.  
 Facing the unusual enzyme kinetics of YdeH, we performed in vitro inhibition 
assays under fixed conditions. To our knowledge, effective inhibitors of DGC activity 
have not been identified so far. Some recently described compounds are able to repress 
biofilm formation supposedly in an indirect fashion rather than binding directly to 
DGCs8,9. We clearly identified direct inhibitors of YdeH activity in mass-spectrometric 
inhibition experiments. The higher affinity of MANT-GTPγS compared to MANT-GTP may 
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be due to stronger interactions of the bulky sulfur with surrounding amino acid residues 
in the binding pocket of YdeH. The TNP group is quite rigid and relatively polar. It can be 
speculated that it is located in a large and rather polar compartment in the binding 
pocket of YdeH and, thus, is responsible for the higher affinity of TNP-GTP compared to 
MANT-substituted guanine nucleotides. The affinities of MANT/TNP-nucleotides to DGCs 
seem to be lower compared to those of other cyclase families (adenylyl or guanylyl 
cyclases). However, absolute affinities cannot be determined due to the exceptional 
enzyme kinetics of YdeH for which reason we only state relative affinities for MANT/TNP 
nucleotides. It is likely that the lower affinities can be attributed to a different binding 
mechanism. This is consistent with a previous report20: The authors state that the 
nucleotide binding mode of DGCs is substantially different compared to mACs. 
Regardless of the relatively low affinity, it has become obvious that affinities of guanine 
nucleotides are significantly higher in comparison to all other examined purine and 
pyrimidine nucleotides. Hence, we suggest that GTP serves as an auspicious core 
structure for the development of potent DGC inhibitors. However, sufficient cell 
membrane permeability often represents a great challenge with regard to the 
establishment of efficient therapeutic strategies. Hence, the development of lipophilic 
pronucleotide inhibitors can offer new perspectives in the treatment of persistent biofilm-
related infections. 
 Most of the examined nucleotide derivatives (except for guanine nucleotide-based 
derivatives) have a very low affinity to YdeH, and an inhibitory effect could not be shown 
in mass-spectrometric activity assays. In contrast, the described fluorescent experiments 
are very suitable for detecting binding events even in case of low affinity inhibitors. 
Additionally, competition assays with NTPs can provide a fast estimation of affinities. To 
our knowledge, this is the first fluorescence-based analysis of a DGC and offers a very 
elegant possibility to circumvent the problems arising from the unusual enzyme kinetics. 
As a first approximation, the identification of newly developed inhibitors via binding to 
DGCs can be accomplished straightforwardly by fluorescence spectroscopy in a high-
throughput manner given the fact that YdeH can be purified in large quantities. 
 In conclusion, our present study provides insights into the interaction of MANT 
nucleotides with the DGC YdeH. Binding events were monitored via FRET-based and 
direct fluorescence experiments and the influence of potential DGC inhibitors was 
analyzed by sensitive HPLC-coupled tandem mass spectrometry. We identified direct 
DGC inhibitors based on GTP derivatives. Hence, our results provide a promising starting 
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point for the development of effective DGC inhibitors with the objective of inhibiting the 
formation of highly persistent biofilms via the influence of intracellular c-di-GMP 
metabolism. 
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6. Summary 
6.1 Summary in English 
Background 
Guanosine 5’-triphosphate (GTP) serves a central substrate of a diverse set of proteins 
and enzymes which are involved in specific signaling pathways in both eukaryotes and 
prokaryotes. These pathways are responsible for a variety of different cellular functions 
and the involved proteins and enzymes can play a key role in the development of 
dangerous diseases. 
 
Fluorescence Assay for Ras Proteins 
Mutated Ras oncogenes are involved in the progress of cancer. A luminescence-based 
microwell plate assay for real-time monitoring of the GTPase activity of wildtype and 
mutated Ras proteins was established. The emission intensity of the applied lanthanide 
complex quickly responds to changes in analyte concentration. The activity of various 
Ras proteins and the influence of a regulator as well as of a downstream effector was 
examined. The presented assay can serve as a cheap, easy, and robust platform for 
high-throughput screening of regulators affecting the GTPase activity of Ras proteins. 
 
HPLC-MS/MS Assay for Di-Guanylate Cyclases 
The formation of bacterial biofilms is the major cause of many chronic infections. Cyclic 
3’:5’-di-guanosine monophosphate (c-di-GMP) is a ubiquitous second messenger in 
bacteria and is involved in the regulation of biofilm formation. A highly specific and 
sensitive HPLC-MS/MS method was developed and applied to the determination of the 
in vitro activity of the di-guanylate cyclase (DGC) PleD* and the in vivo quantitation of 
c-di-GMP in bacterial liquid cultures at different stages of growth. In Escherichia coli, 
intracellular c-di-GMP concentrations change in a growth dependent manner. Thus, the 
established quantitation method can serve as a valuable tool to gain more detailed 
insights into the complex c-di-GMP regulatory system.  
 Most chronic infections such as in the airways of patients with cystic fibrosis result 
from the formation of robust bacterial biofilms which are resistant to antimicrobial 
treatment due to the complex biofilm architecture. DGCs synthesize c-di-GMP which, at 
high concentrations, induces biofilm formation. Hence, DGCs represent pharmacological 
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targets for potential inhibitors of c-di-GMP synthesis. The affinities of 2’(3’)-O-(N-
methylanthraniloyl) (MANT)- and 2’,3’-O-(2,4,6-trinitrophenyl) (TNP)-substituted 
nucleotides to the model DGC YdeH from Escherichia coli were examined in 
fluorescence-based competition assays. Relative affinites were determined using the 
established HPLC-MS/MS method. The presented fluorescence-based assay can be used 
to initially screen potential DGC inhibitors even with low affinities. 
 
Conclusions 
In conclusion, this work describes the development and application of two novel 
analytical methods for the analysis of GTP-converting proteins and enzymes and 
demonstrates the advantages and disadvantages of each method. However, the choice 
of the appropriate method for a specific scientific question can essentially contribute to 
the elucidation of the complex signaling networks based on the conversion of GTP. 
 
 
6.2 Summary in German 
Hintergrund 
Guanosine-5’-triphosphat (GTP) stellt ein wichtiges Substrat einer Gruppe 
verschiedenster Proteine und Enzyme dar, die sowohl in Eukaryoten als auch in 
Prokaryoten mit spezifischen Signaltransduktionswegen in Verbindung stehen. Diese 
Signalwege sind für eine Vielzahl verschiedener zellulärer Funktionen verantwortlich und 
die beteiligten Proteine und Enzyme können eine zentrale Rolle bei der Entstehung 
gefährlicher Krankheiten spielen. 
 
Fluoreszenzassay für Ras-Proteine 
Mutierte Ras-Onkogene sind an der Entwicklung von Krebs beteiligt. Es wurde ein 
Lumineszenz-basierter Mikrotiterplattenassay zur Echtzeit-Bestimmung der GTPase-
Aktivität von Wildtyp- und mutierten Ras-Proteinen aufgebaut. Die Emissionsintensität 
des eingesetzten Lanthanoidkomplexes spricht schnell auf Änderungen der 
Analytkonzentration an. Die Aktivität verschiedener Ras-Proteine und der Einfluss eines 
Regulators sowie eines nachgeschalteten Effektors wurden untersucht. Der dargestellte 
Assay kann als preiswerte, einfache und robuste Plattform für das 
Hochdurchsatzscreening von Regulatoren, die die GTPase-Aktivität beeinflussen, dienen. 
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HPLC-MS/MS-Assay für Di-Guanylatzyklasen 
Die Bildung bakterieller Biofilme ist die Hauptursache vieler chronischer Infektionen. 
Zyklisches 3’:5’-Di-guanosinmonophosphat (c-di-GMP) ist ein universeller second 
messenger in Bakterien und ist an der Regulation der Biofilmbildung beteiligt. Es wurde 
eine hochspezifische und sensitive HPLC-MS/MS-Methode entwickelt und für die 
Bestimmung der in vitro-Aktivität der Di-guanylatzyklase (DGC) PleD* und die in vivo 
Quantifizierung von c-di-GMP in Bakterien-Flüssigkulturen bei verschiedenen 
Wachstumsphasen angewandt. Bei Escherichia coli ändern sich die intrazellulären 
c-di-GMP-Konzentrationen in Abhängigkeit vom Wachstum. Auf diese Weise kann die 
entwickelte Quantifizierung als wertvolle Methode eingesetzt werden, um detailliertere 
Einblicke in das komplexe System der c-di-GMP-Regulation zu erhalten. 
 Die meisten chronischen Infektionen, wie bei Mukoviszidosepatienten, beruhen 
auf der Bildung robuster bakterieller Biofilme, die aufgrund der komplexen 
Biofilmarchitektur resistent gegen konventionelle Antibiotika sind. DGCs bilden c-di-GMP, 
das bei höheren Konzentrationen die Biofilmbildung induziert. Folglich stellen DGCs 
hochinteressante pharmakologische Zielstrukturen für potentielle Inhibitoren der 
c-di-GMP-Synthese dar. Die Affinitäten von 2’(3’)-O-(N-Methylanthraniloyl) (MANT)- und 
2’,3’-O-(2,4,6-Trinitrophenyl) (TNP)-substituierten Nukleotiden zur Modell-DGC YdeH aus 
Escherichia coli wurden in fluoreszenz-basierten Kompetitionsassays untersucht. Relative 
Affinitäten wurden mit Hilfe der etablierten HPLC-MS/MS-Methode bestimmt. Der 
dargestellte Fluoreszenz-basierte Assay kann zum Screening von DGC-Inhibitoren 
benutzt werden, auch wenn diese nur relativ niedrige Affinitäten aufweisen. 
 
Schlussfolgerungen 
Abschließend kann man festhalten, dass in dieser Arbeit mehrere analytische Methoden 
zur Analyse GTP-umsetzender Proteine und Enzyme eingeführt wurden und dass jede 
Methode sowohl Vor- als auch Nachteile mit sich bringt. Wenn jedoch eine angemessene 
Methode für eine spezielle wissenschafltliche Fragestellung ausgewählt wird, kann man 
zur Aufklärung der komplexen Netzwerke der Signalweiterleitung, die auf dem Umsatz 
von GTP basieren, entscheidend beitragen. 
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